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INTRODUCTION 
Meningitis is a one of the important cause of morbidity and mortality 
worldwide. Still it continues to one of lethal infections especially in a 
developing country like ours. Since the mortality is very high prompt, early 
definite initiation of treatment could save lot of lives. For presumptive 
initiation of treatment, simple and cost effective investigations giving a clear 
and definite diagnosis would of great help to the physician 
The present work is a modest attempt at briefly looking at the profile of 
meningitis patients in a tertiary care setup. It also tries imply the significance of 
various parameters that aid us to diagnose a meningitis etiologically  and 
whether a once considered vital investigation like CSF chloride levels hold   
good at aiding and abetting in clear diagnosis. 
It is very well known fact that CSF chloride levels were decreased in 
bacterial meningitis including tuberculous meningitis. Infact in tuberculous 
meningitis it was low compared to pyogenic meningitis. In viral meningitis 
CSF chloride levels were unaltered.  
 
 
 
 
  
 
 
AIMS AND OBJECTIVES 
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AIMS OF THE STUDY 
 
To study the cerebrospinal fluid chloride levels in various types of  
meningitis compare  along with other routine investigations done on meningitis 
patients.
  
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
Meningitis is a syndrome characterized by inflammation of meninges of 
the brain and spinal cord 
PROBLEM STATEMENT 
The incidence differs from country to country depending upon its 
population demography, environmental and social factors along with the 
medical resources. On the whole its incidence is increasing in the developing 
countries and it is presumed incidence to be higher than reported.  
In the western world the trend is such that the incidence is decreasing 
but still is a significant source of morbidity and mortality. 
 
HISTORY 
Meningitis is known since the period of Hippocrates. His works have a 
mention of meningitis. Sir Robert whytt was the first to describe 
tuberculousmeningitis
[1]
 by the year 1768 posthumously In 1805,first outbreak 
of meningitis was documented in Geneva.Gaspard vieusseux, Andre matthey 
and Elisa north described epidemic meningococcal meningitis. Subsequently 
many epidemics were reported. In 1840,there were further outbreaks in Africa. 
One of the major outbreaks was that in Nigeria and Ghana. 
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In 1887, Austrian bacteriologist Anton Vaykselbaum was the first to 
report meningococci as a causative organism in bacterial meningitis. 
Subsequently other organisms. Streptococcus pneumoniae and Haemophilus 
influenza
[1]
 . The technique of lumbar puncture was demonstrated and an early 
analysis of cerebrospinal fluid was done by Henrich Quincke in 1891. 
The clinical features of meningitis were described by Russian physician 
Vladimir kernig (1884) and polish physician Josef brudzinski (1899). Kernig’s 
sign and Brudzinski’s sign were named after them. 
Influenza A, Influenza B ,Adenoviral infection causing meningitis were 
later described after world war 2. AA Smorodinstev recorded 200 different 
viral meningitis with subtyping them. 
 
VACCINES 
In 1906 horses were used to create antibodies against meningococcal 
bacteria.
[8] 
American scientist Simon Flexner developed this to decrease death and 
disability rates. The advent of haemophilus vaccines caused a great reduction in 
the prevalence of meningitis due to haemophilus.
[8] 
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ANTIBIOTICS 
Initial successful treatment of meningitis was with serum therapy for 
meningococcal meningitis by Georg joachmann and Simon Flexner.
[1] 
In 1944 penicillin was used for treatment of meningitis and marked by 
good response. Francois schwentker used sulfonamides and Chester keefer 
used penicillin appropriately to give results. 
 
STEROIDS 
Evidence emerged that use of steroids in tuberculous meningitis could 
improve the disability rates.  It revolutionized therapeutics in meningitis 
patients.In 2007, Advisory committee on Immunization Practices recommends 
routine meningococcal vaccine to children of 11 and 12  years. 
In India, National immunization schedule has routine haemophilus 
vaccine. The government medical services ensures that each and every children 
are vaccinated. Apart from this the Indian Association of Paediatrics (IAP) 
vaccination schedule recommends pneumococcal vaccine. Also IAP 
recommends vaccination against Japanese encephalitis and Meningococci.
[2][8]
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DESCRIPTION 
Meningitis could be the inflammation involving the 3 layers of 
membranes that encase the CNS structures. They involved structures are: 
 1.Dura the outer membrane tough in nature 
2. Arachnoid middle membrane lacy and weblike 
3.The subarachnoid space containing feeding blood vessels to brain and 
spinal cord may be involved. 
Anatomical classification of meningitis: 
Pachymeningitis – inflammation of the dura.less common. 
Leptomeningitis – inflammation of arachnoid and sub arachnoid space. 
More common 
 Meningitis can be divided into the following categories: 
Bacterial meningitis 
Granulomatous meningitis 
Aseptic meningitis 
    Meningitis can also be classified as  
Acute less than 24 hours – considered almost to be bacterial 
Subacute 1 – 7 days 
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Chronic > 7 days 
RISK FACTORS 
Extremes of ages both less than 5 or greater than 60 
Diabetes mellitus 
Immunosuppression  
HIV infection especially encapsulated organisms 
Crowding 
Bacterial endocarditis 
Chronic kidney disease 
Adrenal insufficiency 
Post splenectomy status 
Alcoholism 
Chronic liver disease 
Sickle cell disease 
Contiguous infection 
Head injury patients 
Patients who underwent neurosurgical procedures like vp shunts 
Iv drug abusers 
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Thalassemia major 
Hypoparathyroidism 
Cystic fibrosis 
Congenital cranial deformities 
Malignancy 
ETIOLOGY 
Bacterial meningitis 
Streptococcus pneumoniae gram positive coccus the most common 
cause of bacterial meningitis worldwide.[2]  It is the commonest organism 
associated in skull base fractures and CSF leak. It may be associated with 
pneumonia, endocarditis ( as in Austrian syndrome )   and /or sinusitis. It may 
be present in healthy individuals in pharynx and nasal cavity. Choroid plexus 
seeding from bacteremia / contiguous spread seems the mode of causation of 
meningitis.[3][4][5] 
Niesseria meningitides , gram negative diplococcus in nasopharynx of 
normal individuals .It is the leading cause of meningitis in young adults as of 
now.It invades the airway epithelium by way of penetration. Sporadic cases by 
B , C , Y strains . Epidemics caused by A , C strains.[6][7] 
Haemophilus influenzae a small gram negative coccobacillus. It’s 
normal habitat is the upper airways. Encapsulated type b strain was commonly 
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isolated strain. Since the advent of Hib vaccine the overall incidence has 
drastically fallen. [12][13] 
Listeria monocytogenes, small gram positive bacillus characterized by 
high rates of mortalities. Most common mode of infection is food borne. It is 
associated with outbreaks in people consuming contaminated milk cheese and 
alfalfa tablets.It has a predilection to infect children and elderly. 
          Staphylococci, gram positive cocci present in normal skin flora . It 
causes Meningitis in patients who underwent neurosurgical procedures, head 
injury, CSF Shunts and infective endocarditis. S.epidemidis is frequent offender 
in shunt infections. 
Sterptococccus agalactiae , gram positive coccus inhabitant of lower 
gastro intestinal tract/ female genitalia . It is common cause of neonatal 
meningitis but known to affect diabetics, alcoholics, hepatic, renal failure 
patients. 
Many aerobic gram negative bacteria like Escherichia coli, Klebsiella 
pneumoniae,Serratia marcescens, Pseudomonas aeruginosa , Salmonella 
species. A peculiar risk factor involves disseminated strongylodiasis causing 
gram negative bacillary bacteremia. The movement of Strongyloides stercoralis 
larvae across the gut helps the gram negative bacilli to translocate the gut 
causing bacteremia subsequently meningitis.[9][10][11] 
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Tuberculous meningitis 
           In India this one of the most common form of meningitis as compared 
with the western world by the shear prevalence of pulmonary and other forms 
of tuberculosis which favours the CNS dissemination. CNS tuberculosis 
accounts about 15% of tuberculosis of this Tb meningitis is by far the 
commonest CNS presentation of tuberculosis. The mortality rate is as high as 
27%. With the epidemic of HIV infections there are more newly acquired and 
reactivated tuberculous infections.[14][15] More than 50% of HIV infected 
patients are found to have had tuberculosis infection during the course of their 
illness. Thus these patients serve as an active reservoir to the spread of TB in 
the community.  
Virtually all tuberculous infections of the CNS are caused by the human 
tubercle bacillus, Mycobacterium tuberculosis. Infections caused by M. bovis 
acquired from the ingestion of contaminated milk are now quite rare, as are 
infections caused by other nontuberculous mycobacteria (NTM) pathogenic for 
human, except in immunocompromised patients, where infection of M. avium 
and M. intercellulare are common.[19]
 
Viral meninigitis       
Acute viral meningitis of the central nervous system (CNS) have a 
sudden onset and run a short course over days to weeks.  Certain features of 
viral infections are noteworthy. This includes tropism—viruses may infect 
specific cells and anatomical areas of the nervous system, e.g. anterior horn 
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cells are affected in poliomyelitis, the dorsal root ganglion cells in varicella 
zoster infection and the neurons in rabies. 
Certain viruses (e.g. herpes simplex and varicella zoster) have the ability 
to remain latent in the nervous system and get reactivated months to years later. 
Most viruses replicate in extraneural tissues before invading the CNS and 
involvement of the nervous system is usually only an occasional complication 
of the systemic viral infection. The majority of viruses enter the nervous 
system via the haematogenous route, except herpes simplex and rabies 
viruses.
[20]
 Often the viral agent cannot be identified during the acute illness 
and the diagnosis can only be made retrospectively. Viruses may affect the 
CNS by means other than direct invasion; peri-venous encephalomyelitis 
usually follows a systemic viral infection or vaccinations and is an allergic 
reaction to viral antigen.The following table shows some common viral agents. 
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Fungal meningitis 
Cryptococcus neoformans, an encapsulated yeast-like fungus is the most 
common CNS mycosis. It is found in mammal and bird faeces, particularly in 
pigeon droppings. CNS infection can be meningeal or less commonly 
parenchymal. Disseminated disease occurs commonly in immunocompromised 
while cryptococcomas (granulomas) occur in imm unocompetent hosts. 
Cryptococcal meningitis is thought to be a reactivation of the dormant lesion in 
the lung similar to Ghon’s focus of pulmonary tuberculosis. Basal meningitis 
may cause obstructive hydrocephalus. Focal lesions like cryptococcomas or 
infarction present with focal neurological deficits or seizures. The commonest 
parenchymal sites are the mid-brain and the basal ganglia. Infarctions in basal 
ganglia,internal capsule and thalamus may rarely occur. 
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Aspergillus is a ubiquitous fungus in soil, water, decaying vegetation 
and organic debris. Aspergillus fumigatus, A. terreus, and A. flavus cause CNS 
infection. Spread to CNS occurs haematogenously or by direct inoculation into 
the CNS during surgical procedures or from contiguous structures. CNS 
aspergillosis can present as solitary or multiple lesions, meningitis. 
 
PATHOGENESIS 
          In many cases of meningitis are caused by an infectious organism that 
has colonized or established a localized infection elsewhere in the body. 
Possible sites of colonization or infection include the skin, the nasal cavity, 
pharynx, the respiratory tract, the gastrointestinal (GI) tract, and the 
genitourinary tract. The organism enters the submucosa at the above sites by 
escaping host defenses (eg, physical barriers, local immunity, and phagocytes 
or macrophages). An infectious organism (ie, a bacterium, virus, fungus, or 
parasite) can gain access to the central nervous system  and cause meningeal 
disease via any of the 3 following pathways: 
 Blood stream invasion followed  hematogenous seeding of the CNS 
 A neuronal (eg, olfactory and peripheral nerves) pathway by in retrograde 
fashion  (eg, Naegleria fowleri or Gnathostoma spinigerum) 
 Contiguous spread (eg, sinusitis, congenital malformations, trauma, OM 
or direct inoculation during intracranial manipulation) 
Bloodstream invasion and subsequent seeding is the most common mode of 
spread for most agents. This pathway is very peculiar of meningococcal, 
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cryptococcal, syphilitic, and pneumococcal meningitis. Infrequently, meningitis 
arises secondary to invasion via septic thrombi or osteomyelitic erosion from 
infected adjacent structures. Meningeal seeding may occur with a direct 
bacterial inoculate during injury, neurosurgery. Meningitis in the newborn is 
usually transmitted vertically, involving pathogenic organisms that have 
colonized the maternal intestinal or genital tract, or horizontally, from nursing 
staff or caretakers at home. 
Local extension from extracranial infection (eg, OM, mastoiditis, or 
sinusitis) is a common cause. Possible access for the migration of pathogens 
from the middle ear to the meninges are: 
 The bloodstream 
 Preformed tissue planes (eg, posterior fossa) 
 Temporal bone fractures 
 The oval/ round window membranes of the labyrinths 
 
The brain is naturally protected from immune mechanism of host by the 
barrier that the meningeal coverings form between the bloodstream and the 
brain. Normally, this protection is a beneficial as the barrier prevents the 
immune system from attacking the CNS. In meningitis, the blood-brain barrier 
can becomes broken. Once infectious agents have found their way to the brain, 
they are not easily accessible to the immune system and can spread. When the 
host tries to fight the infection, the problem aggravates, blood vessels become 
leaky and allow plasma, WBCs, and host immune related cytokines to enter the 
CNS. This process, in turn, causes brain edema and can finally result in 
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hypoperfusion to parts of the brain, leading to deterioration of infection.
 
 Based 
on the severity of pyogenic meningitis, the inflammatory process may remain 
localised to the subarachnoid space. In less severe forms, the pia matar is not 
penetrated, and the underlying brain parenchyma remains intact. However, in 
more extreme forms of pyogenic meningitis, the pial barrier is breached, and 
the underlying CNS is invaded by the inflammatory process. Thus, pyogenic 
meningitis may lead to widespread parenchymal destruction, particularly when 
not treated. 
Multiplying bacteria, increasing numbers of WBC’S, cytokine-induced 
alterations in membrane transport, and increased vascular and membrane 
permeability accentuate the infectious process in pyogenic meningitis. These 
are reasons for the peculiar changes in CSF cell count, pH, lactate, protein, and 
glucose in patients with this disease. Exudates extend throughout the 
cerebrospinal fluid, particularly to the basal cisterns, resulting in: 
 Cranial nerves getting affected (eg, cranial nerve VIII, with resultant 
deafness) 
 Disruption of CSF pathways (causing obstructive hydrocephalus) 
 Vasculitis and thrombophlebitis (causing cerebral ischemia) 
Intracranial pressure and cerebral fluid 
     A major complication of meningitis is the development of raised 
intracranial pressure (ICP). The mechanism of this complication is complex 
and may involve a lot of proinflammatory substances  as well as mechanical . 
Interstitial edema (leading to obstruction of CSF pathway, as in 
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hydrocephalus), cytotoxic edema (swelling of cellular elements of the CNS 
through the release of toxic substances from the organisms and neutrophils), 
and vasogenic edema (increased blood brain barrier leakiness) are all hand in 
hand. Without medical management, the cycle of decreasing cerebrospinal 
fluid, worsening cerebral edema, and increasing ICP proceeds unhampered. 
Ongoing endothelial injury may result in vasospasm and thrombosis  may lead 
to stenosis of major and minor vessels. Systemic hypotension (septic shock) 
also may decrease cerebrospinal fluid  , and the patient soon dies as a result of 
systemic complications or diffuse cerebral ischemic injury.
[28][29] 
Cerebral edema 
Increased cerebrospinal fluid viscosity results from the inflow of plasma 
components into the subarachnoid space and decreased venous outflow 
resulting to interstitial edema. The accumulation of the products of  
inflammation  other cellular activation leads to cytotoxic edema. The resulting 
brain edema (ie, vasogenic, cytotoxic, and interstitial) contributes to 
intracranial pressure and a subsequent hypoperfusion. Anaerobic metabolism 
happens, resulting in raised lactate levels and hypoglycorrhachia. Also, 
hypoglycorrhachia results from decreased glucose transport into the CSF 
compartment. If this process is not interrupted by appropriate treatment, 
reversible neuronal dysfunction or permanent neuronal damage results.
[29] 
17 
 
Cytokines and secondary mediators in bacterial meningitis 
       Important knowledge of mechanism of meningitis include insight into 
the major roles of cytokines (eg, tumor necrosis factor alpha [TNF-α] and 
interleukin [IL]-1), chemokines (IL-8), and other proinflammatory molecules in 
causing  pleocytosis and neuronal damage during  of pyogenic meningitis. 
Raised cerebrospinal fluid levels of TNF-α, IL-1, IL-6, and IL-8 are 
characteristic findings in pyogenic meningitis. Cytokine levels, including those 
of IL-6, TNF-α, and IFN- gamma, have been found to be increased in patients 
with viral meningitis. The hypothesised events involving the inflammation 
mediators in pyogenic meningitis start with the exposure of  endothelial cells, 
leukocytes, microglia, astrocytes, and meningeal macrophages to bacterial 
products released during multiplication and death; this exposure results in the 
production of cytokines and proinflammatory mediators. The cycle is  initiated 
by the adhesion of the bacterial components like peptidoglycan and 
lipopolysaccharide to pattern-recognition receptors, such as the Toll-like 
receptors (TLRs).TNF-α and IL-1 are most prominent among the cytokines that 
mediate this inflammatory cascade. TNF-α is a glycoprotein derived from 
activated monocyte-macrophages, lymphocytes, astrocytes, and microglial 
cells.IL-1 is also produced  by activated mononuclear phagocytes and results in 
the induction of fever during bacterial infections. Both IL-1 and TNF-α have 
been detected in cerebrospinal fluid of  individuals with pyogenic meningitis. 
In trial models of meningitis, they appear early during the disease process and 
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have been detected within 30-45 minutes of intracisternal endotoxin 
inoculation. 
Many secondary mediators, such as IL-6, IL-8, nitric oxide, 
prostaglandin E2 (PGE2), and platelet activation factor (PAF), are presumed to 
augment this inflammatory process, either synergistically or independently. IL-
6 induces acute-phase reactants in response to bacterial infection. The 
chemokine IL-8 propagates neutrophil chemoattractant responses initiated by 
TNF-α and IL-1[28].Nitric oxide a free radical substance that can be cytotoxic 
when produced in excess amounts. PGE2, a product of cyclooxygenase (COX), 
is thought to participate in the induction of increased blood-brain barrier 
permeability. PAF, with its elaborate biologic activities, is believed to catalyze 
the formation of thrombi and the activation of clotting factors within the blood 
vessels. However, the exact roles of all these secondary mediators in meningitis 
remain unclear.This finally results in vascular endothelial injury and raised 
blood-brain barrier permeability, leading to the entry of many blood 
components into the subarachnoid space. This results to vasogenic edema and 
raised cerebrospinal fluid protein levels. In response to the cytokines and 
chemotactic substances, neutrophils migrate from the blood and invade the 
damaged blood-brain barrier, resulting the profound neutrophilic pleocytosis 
peculiar to pyogenic meningitis
[29]
. 
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Genetic predisposition to inflammatory response 
The inflammatory response and the release of proinflammatory 
mediators are important  to the migration of excess neutrophils to the 
subarachnoid space. The activated neutrophils release cytotoxic agents, 
including oxidative agents and metalloproteins that cause collateral damage to 
brain parenchyma. 
Pattern recognition receptors, of which TLR A4 (TLRA4) ,  result 
increasing the myeloid differentiation 88 (MyD88)-dependent pathway and 
increased production of proinflammatory mediators
[29]
.  
Bacterial seeding 
Bacterial seeding of the meninges usually occurs through blood. In 
patients without an documented foci of infection, local tissue and hematogenic 
spread by bacteria that have occupied the nasopharynx may be a common 
source. Most of the meningitis-causing bacteria are carried in the nasopharynx, 
often asymptomatically. Most meningeal pathogens are transmitted through the 
respiratory pathways, including Neisseria meningitidis(meningococcus) and S 
pneumoniae(pneumococcus). 
Few respiratory viruses are thought to facilitate the entry of bacterial 
agents into the vascular compartment, by damaging mucosal defenses. Once 
the organism are in the blood, they must escape immune mechanisms like 
antibodies, complement-mediated bacterial killing, and neutrophil 
phagocytosis. Hematogenous seeding into far off sites, including the brain, 
occurs.
[29]
 The specific mechanisms by which the infectious agents reaches the 
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subarachnoid space remain not known. Once inside the brain, the infectious 
organisms survive because host immune mechanisms (eg, immunoglobulins, 
neutrophils, and complement components) appear to be limited in this body 
compartment. The presence and multiplication of infectious agents remain 
unabated and incite the cascade of meningeal inflammation already. 
 
Tuberculous meningitis 
Like all other forms of tuberculosis, CNS infection begins with 
inhalation of infectious particles. On reaching the alveoli, airborne droplet 
nuclei, each containing small number of organisms, multiply either within the 
alveolar space or within the alveolar macrophages. For first 2 to 4 weeks, when 
there is virtually no inflammatory response, haematogenous dissemination of 
the organism is believed to occur in every case. Two to four weeks following 
infection, cell-mediated immunity to bacteria develops. A tubercle is formed, 
consisting of macrophages, lymphocytes and other cells surrounding a necrotic 
caseous centre. Fate of these tubercles and subsequent course of infection are a 
function of both the immunologic capacity of the host and other incompletely 
understood genetic factors. When there is robust immunity, minute caseous foci 
are formed only to be eliminated completely by the surrounding macrophages 
leaving no residua. Less efficient but still effective immune response results in 
larger caseous foci which, despite fibrous encapsulation,continue to shelter 
viable mycobacteria, which may cause reactivated disease if host’s immune 
vigilance lessens. In the presence of profound immunodeficiency, primary 
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tubercle continues to grow, the caseous centre may liquefy, organisms 
proliferate and tubercle ultimately ruptures, discharging organisms into the 
surrounding tissue. 
When these events occur within the brain and meninges and the so-
called Rich’s foci ruptures discharging the organism in the subarachnoid space, 
tuberculous meningitis results. The vascular choroid plexus are common sites 
for tubercle formation and also common site for rupture of a tubercle as also 
foci located on the surface of the brain. Those tubercles located deep in the 
brain or spinal cord parenchyma will enlarge to form tuberculoma or 
tuberculous abscesses.
[14][15] 
 
Meningeal Exudate and Meningitis 
The primary pathological event is the formation of thick tuberculous 
exudates within the subarachnoid space. These exudates diffuse with particular 
prominence at the base of the brain irrespective of the location of the 
discharging focus. The exudates accumulate around the interpeduncular 
fossa,enveloping the optic nerves at the chiasma and extending over the pons 
and cerebellum, often into the sylvian fissures and rarely up along the cerebral 
hemispheres. Thus, other cranial nerves such as III, IV, VI, VII, and VIII may 
be involved in the subarachnoid space in varying degrees.In appearance, the 
exudate is gelatinous and frequently nodular. 
Microscopically, it consists of polymorphonuclear leucocytes, red blood 
cells, macrophages and lymphocytes within a fibrin network. Typical 
tubercles,occasionally with large zones ofcaseation necrosis develop within the 
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exudate. In untreated cases, a large number of tubercle bacilli can be detected 
at the margins of caseous necrosis. With treatment fibroblasts and elements of 
connective tissues replace the exudates.
[14] 
 
Spinal TB meningitis 
Spinal meningitis is a common asymptomatic accompaniment of cranial 
meningitis. In most cases, there is extension of basal exudates downwards. 
However, tuberculous spinal arachnoiditis can present first time as spinal cord 
disorder and may move upwards often asymptomatically into the cranial 
cavity.
[17] 
Vertebral involvement accounts for more than 50% of all skeletal 
tuberculosis. Thoracic and lumbar spines are most commonly involved due to 
paucity of movement. Multiplicity of vertebral body involvement (up to 50%) 
and posterior element lesions are frequently seen, which may lead to sudden 
paraplegia due to ‘concertina’ collapse of the involved vertebrae or vascular 
thrombosis. In about 70% of cases, paraplegia recovers completely if treated 
promptly
[16] 
 
CLINICAL FEATURES 
Meningitis can present as either an acute fulminant illness that 
progresses rapidly in a few hours or as a subacute infection that progressively 
worsens over several days. The classic clinical triad of meningitis is fever, 
headache, and nuchal rigidity, but the classic triad may not be present. A 
decreased level of consciousness occurs in >75% of patients and can vary from 
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lethargy to coma. Fever and either headache, stiff neck,or an altered level of 
consciousness will be present in nearly every patient with bacterial meningitis. 
Nausea, vomiting, and photophobia are also common complaints. Seizures 
occur as part of the initial presentation of bacterial meningitis or during the 
course of the illness in 20–40% of patients. Focal seizures are usually due to 
focal arterial ischemia or infarction, cortical venous thrombosis with 
hemorrhage, or focal edema. Generalized seizure activity and status epilepticus 
may be due to hyponatremia, cerebral anoxia, or, less commonly, the toxic 
effects of antimicrobial agents.
[3][5][6]
 
Raised ICP is an expected complication of bacterial meningitis and the 
major cause of obtundation and coma in this disease. More than 90% of 
patients will have a CSF opening pressure >180 mmH2O, and 20% have 
opening pressures >400 mmH2O. Signs of increased ICP include a 
deteriorating or reduced level of consciousness, papilledema,dilated poorly 
reactive pupils, sixth nerve palsies, decerebrate posturing, and the Cushing 
reflex (bradycardia, hypertension, and irregular respirations).  
One of the most important  clues is the rash of meningococcemia, which 
begins as a diffuse erythematous maculopapular rash resembling a viral 
exanthem; however, the skin lesions of meningococcemia rapidly become 
petechial. Petechiae are found on the trunk and lower extremities, in the 
mucous membranes and conjunctiva, and occasionally on the palms and 
soles.
[6] 
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Characteristic skin  rash in a patient with meningococcaemia
[6][7] 
The clinical picture of TBM is quite variable, with substantial 
differences among patients of different ages. The clinical manifestations 
depend upon a variety of factors related both to the organism and the host like 
pre-existing malnutrition,coexistence of HIV infection, BCG vaccination, etc. 
Among children, majority of cases (75% to 85%) are below the age of 5 years. 
The onset of the disease may be acute, i.e. within 6 days, sub-acute or gradual, 
taking more than 3 weeks to develop. Among adults, the disease typically 
presents in a somewhat indolent fashion. The classical form of the disease 
evolves through a prodromal stage, a stage of meningeal irritation, leading to a 
stage of diffuse or focal cerebral involvement. Nausea, vomiting, anorexia, 
abdominal pain, constipation and behavioural changes are among most 
commonly reported symptoms. Headache is reported in less than 25% of 
children than in adults (50% to 75%) . Some degree of fever is usual, but it may 
be of low grade and absent in 10% to 15% of children and 25% to 30% of 
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adults. As the disease progresses, signs of meningeal irritation will develop, 
though it is less commonly seen in infants, instead fullness of fontanelle is 
seen. Seizures may present at any stage of the disease. Ten to twenty per cent 
of subjects may have seizures during the initial period, later it may be seen in 
up to 50% of cases. Psychobehavioural changes are frequently observed at 
onset in adults.
[5]
 Signs and symptoms of raised intracranial pressure like 
enlargement of head in children and papilloedema may be seen early in the 
disease.
 
Focal neurological signs, which are common in the later part ofthe 
disease, most frequently consists of unilateral or, less commonly, bilateral 
cranial nerve palsies. Most frequently affected is the sixth cranial nerve 
followed by III, IV, VII and less commonly II, VIII, X, XI and XIIth.
[17][18]
 
Visual impairment may be there due to optochiasmatic arachnoiditis, 
tuberculoma compressing the optic nerve, secondary optic atrophy from 
papilloedema or ethambutol toxicity
[18]
. Fundoscopic examination may reveal 
papilloedema, disc pallor or choroid tubercles, which are seen in 10% of cases 
with TBM and it is a very useful clue to diagnosis. There may be isolated 
pupillary involvement without other features of III nerve palsy. Rarely, there 
may be internuclear ophthalmoplegia and horizontal gaze paresis due to 
intrinsic brainstem lesion. Other common findings include hemiparesis, 
monoparesis and aphasia due to ischaemic infarction in 10% to 45% of cases. 
Less frequently neurological signs include a variety of abnormal movements 
like chorea, hemiballismus, athetosis, myoclonus and cerebellar ataxia
[15][16]
. 
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Persistent movement disorder may persist even after recovery from meningitis, 
especially among children. 
In untreated cases, there may be deterioration of the consciousness from 
drowsiness to deep coma and brainstem dysfunction. Rarely intra-cranial 
bleeding may complicate TBM. Intraventricular haemorrhage may result from 
rupture of tuberculous mycotic aneurysm and parenchymal haemorrhage from 
moyamoya phenomenon of tuberculous arteritis. In order to assess severity of 
the disease and guide to prognosis, it is useful to stage patients clinically at the 
time of diagnosis,based on the British Medical Research Council classification. 
 
Stage 1 (early disease) 
Patient has meningeal signs only, consciousness is undisturbed and no 
focal neurological signs are present. 
 
Stage 2 (medium severity) 
Consciousness is disturbed but the patient is not comatose or delirious. 
Focal neurological signs and cranial nerves palsies are present. Raised intra-
cranial pressure may occur secondary to hydrocephalus. In infants, fontanelle 
bulges and head enlarges,and in adults there is papilloedema. 
 
Stage 3 (advanced disease) 
Patient is deeply comatose with evidence of brainstem dysfunction, 
decerebrate or decorticate posturing, fixed dilated pupils, irregular pulse and 
respiration. Untreated patients progress the three stages and usually die. 
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TB Spinal meningitis 
This may be due to involvement of spinal meninges, of spinal cord 
secondary to vasculopathy or tuberculoma, or of the bony elements of the spine 
(caries) with secondary involvement of the cord (Pott’s paraplegia). 
Tuberculous spinal meningitis may be due to secondary spread of cranial 
meningitis or from spinal caries, or may be primary spinal meningitis 
presenting with single or multiple level ascending or transverse 
radiculomyelopathy. Symptoms include fever, spinal pain, radicular pain, 
paraesthesia, combined upper and lower motor features in lower limbs and 
bladder disturbances. Chronic spinal arachnoiditis may be indistinguishable 
from spinal cord compression.
[16][17] 
Vertebral involvement accounts for more than 50% of all skeletal 
tuberculosis. Thoracic and lumbar spines are most commonly involved due to 
paucity of movement. Multiplicity of vertebral body involvement (up to 50%) 
and posterior element lesions are frequently seen, which may lead to sudden 
paraplegia due to ‘concertina’ collapse of the involved vertebrae or vascular 
thrombosis. In about 70% of cases, paraplegia recovers completely if treated 
promptly 
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Viral meningitis 
In viral meningitis, immunocompetent adult patients usually present 
with headache, fever, and signs of meningeal irritation coupled with an 
inflammatory CSF profile . Headache is almost invariably present and often 
characterized as frontal or retroorbital and frequently associated with 
photophobia and pain on moving the eyes. Nuchal rigidity is present in most 
cases but may be mild and present only near the limit of neck anteflexion. 
Constitutional signs can include malaise, myalgia, anorexia, nausea and 
vomiting, abdominal pain, and/or diarrhea. Patients often have mild lethargy or 
drowsiness; however, profound alterations in consciousness, such as stupor, 
coma, or marked confusion, do not occur in viral meningitis and suggest the 
presence of encephalitis or other alternative diagnoses. Similarly, seizures or 
focal neurologic signs or symptoms or neuroimaging abnormalities indicative 
of brain parenchymal involvement are not typical of viral meningitis and 
suggest the presence of encephalitis or another CNS infectious or inflammatory 
process
[20]
. 
 
INVESTIGATIONS 
 
When bacterial meningitis is suspected, blood cultures should be 
immediately obtained and empirical antimicrobial and adjunctive 
dexamethasone therapy initiated without delay . The diagnosis of bacterial 
meningitis is made by examination of the CSF. The need to obtain 
neuroimaging studies (CT or MRI) prior to LP requires clinical judgment. In an 
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immunocompetent patient with no known history of recent head trauma, a 
normal level of consciousness, and no evidence of papilledema or focal 
neurologic deficits, it is considered safe to perform LP without prior 
neuroimaging studies. If LP is delayed in order to obtain neuroimaging studies, 
empirical antibiotic therapy should be initiated after blood cultures are 
obtained. Antibiotic therapy initiated a few hours prior to LP will not 
significantly alter the CSF WBC count or glucose concentration, nor is it likely 
to prevent visualization of organisms by Gram’s stain or detection of bacterial 
nucleic acid by polymerase chain reaction (PCR) assay. 
The classic CSF abnormalities in bacterial meningitis are (1) 
polymorphonuclear (PMN) leukocytosis (>100 cells/μL in 90%), (2) decreased 
glucose concentration ( <40 mg/dL) and/ or CSF/serum glucose ratio of <0.4 in 
~60%), (3) increased protein concentration (>45 mg/dL in 90%), and (4) 
increased opening pressure (>180 mmH2O in 90%). CSF bacterial cultures are 
positive in >80% of patients, and CSF Gram’s stain demonstrates organisms in 
>60%. CSF glucose concentrations <40 mg/dL are abnormal,and a CSF 
glucose concentration of zero can be seen in bacterial meningitis. Use of the 
CSF/serum glucose ratio corrects for hyperglycemia that may mask a relative 
decrease in the CSF glucose concentration. The CSF glucose concentration is 
low when the CSF/serum glucose ratio is <0.6. A CSF/serum glucose ratio <0.4 
is highly suggestive of bacterial meningitis but may also be seen in other 
conditions, including fungal, tuberculous, and carcinomatous meningitis.
[9]
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A 16S rRNA conserved sequence broad-based bacterial PCR can detect 
small numbers of viable and nonviable organisms in CSF and is expected to be 
useful for making a diagnosis of bacterial meningitis in patients who have been 
pretreated with oral or parenteral antibiotics and in whom Gram’s stain and 
CSF culture are negative. When the broad-range PCR is positive, a PCR that 
uses specific bacterial primers to detect the nucleic acid of S. pneumoniae, N. 
meningitidis,Escherichia coli, L. monocytogenes, H. influenzae, and S. 
agalactiae can be obtained based on the clinical suspicion of the meningeal 
pathogen
[5][7]
. The latex agglutination (LA) test for the detection of bacterial 
antigens of S. pneumoniae, N. meningitidis, H. influenzae type b, group B 
Streptococcus, and E. coli K1 strains in the CSF has been useful for making a 
diagnosis of bacterial meningitis but is being replaced by the CSF bacterial 
PCR assay. The Limulus amebocyte lysate assay is a rapid diagnostic test for 
the detection of gram-negative endotoxin in CSF and thus for making a 
diagnosis of gram-negative bacterial meningitis. The test has a specificity of 
85–100% and a sensitivity approaching 100%.[6] Thus, a positive Limulus 
amebocyte lysate assay occurs in virtually all patients with gram-negative 
bacterial meningitis, but false positives may occur. Almost all patients with 
bacterial meningitis will have neuroimaging studies performed during the 
course of their illness. MRI is preferred over CT because of its superiority in 
demonstrating areas of cerebral edema and ischemia. In patients with bacterial 
meningitis, diffuse meningeal enhancement is often seen after the 
administration of gadolinium. Meningeal enhancement is not diagnostic of 
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meningitis but occurs in any CNS disease associated with increased blood-
brain barrier permeability. Petechial skin lesions, if present, should be biopsied. 
The rash of meningococcemia results from the dermal seeding of organisms 
with vascular endothelial damage, and biopsy may reveal the organism on 
Gram’s stain. 
In Tuberculous meningitis typically the cerebrospinal fluid is clear or 
slightly opalescent with raised opening pressure. A cobweb may develop when 
the CSF is allowed to stand for short time, though it is not a specific finding. A 
moderate lymphocytic pleocytosis up to 500 cells/mm3 is characteristic of 
TBM. However, counts of more than 1000/mm3 and predominantly 
polymorphonuclear leucocytes may be found in the early part of the illness.
[18]
 
There is moderate elevation of CSF protein (100 to 500 mg/dL) and depression 
of glucose (<40mg/dL). Hypoglycorrhachia has been correlated with more 
advanced stage of clinical disease and a rise in CSF glucose after therapy 
indicates better prognosis. In tuberculoma, the CSF may be normal or may 
show a lymphocytic pleocytosis with increased protein levels. In spinal 
meningitis, there may be spinal block with CSF xanthochromia, very high 
protein levels (>1 gm/dL) and lymphocytic pleocytosis.
[18]
Identification of 
tuberculous bacilli in the CSF confirms diagnosis though it is difficult. A 
variety of techniques have been proposed.Detection rate is 15% to 20%. It may 
be increased by centrifuging large volume of CSF and preparing a thick smear 
of the deposit, and examination of cobweb. 
32 
 
Traditional culture in Lowenstein-Jensen media is a time consuming 
procedure. Newer radiometric (BACTEC 460 TB) and non-radiometric, semi-
automated and fully automated liquid systems have decreased the time to a 
positive result to 1 to 3 weeks with good rates of positivity (80% to 95%).
[18] 
PCR technique held promise in the confirmation of diagnosis of TBM. It 
has a high specificity (98%) but low sensitivity (56%).Three regions of the M. 
tuberculosis genome are targeted: IS 6110 sequences, MBP 64 gene codes and 
541 bp regions. 
Real-time PCR combines rapid cycle DNA amplification with 
fluorimetry. In cultured samples it has 100% specificity and can detect as few 
as 10 organisms. Nested real-time PCR may further improve the sensitivity. 
Indirect tests that are helpful in the diagnosis of TBM include adenosine 
deaminase level in CSF, radiolabelled bromide partition test, CSF 
tuberculostearic acid level, and mycobacterial antigen and antibody detection 
by ELISA .
[18] 
Contrast-enhanced CT scan and MRI are invaluable in the diagnosis of 
neurotuberculosis but none of the radiological changes are pathognomonic. 
MRI is better than CT scan in detecting diffuse and focal meningeal 
granulomatous lesions, small tuberculoma and focal infarcts.
[19] 
Meningeal enhancement is frequently seen, most commonly in the basal 
subarachnoid cisterns, Sylvian fissures and around brainstem. There may be 
associated hydrocephalus or infarction . Hydrocephalus is the single-most 
common abnormality (50% to 80%), which can be of either communicating or 
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obstructive type. The radiological features of tuberculoma on CT vary 
according to its stage. Mature lesions appear as a well-defined round or oval 
ring enhancing mass with occasionally a target sign. The immature 
tuberculoma are iso/hypodense on plain CT and show ring or nodular contrast 
enhancement. In many cases, solitary tuberculoma may be indistinguishable 
from abscess, tumour and cysticercus granuloma . On MRI, solid caseating 
granulomas are isointense on T1 and iso/hypointense on T2-weighted images. 
Occasionally, there may a central hyperintense area with hypointense rim on 
T2-weighted images. Non-caseating granulomas are usually hypointense in T1 
and hyperintense in T2-weighted images, with homogeneous contrast 
enhancement. Conglomerated lesions are often seen in gadolinium-enhanced 
MRI. Magnetic resonant spectroscopy (MRS) can provide biochemical 
information from a tissue. MRS of a tuberculoma usually shows presence of 
lipid/lactate peak with increased choline:creatine ratio, but usually less than 
two. 
Magnetisation transfer imaging with contrast is a more sensitive 
imaging modality in tissue characterisation and helpful in differentiating 
tuberculoma from cysticercus granuloma.
[17][19] 
Non-invasive MRI has replaced conventional myelographic techniques 
in detecting spinal diseases. Abnormalities on MRI have included obliteration 
of the subarachnoid space, clumping of nerve roots, oedema of cord, central 
and ecentric cavitation of the cord, and extensive signal abnormalities within 
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the substance of the cord. Intramedullary tuberculoma are hypointense in both 
T1- and T2-weighted images with marked gadolinium enhancement. 
 
 
 
Cect brain showing basal enhancing exudates with obstructive 
hydrocephalus 
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 In the diagnosis of viral meningitis  CSF  profile shows  pleocytosis, a 
normal or slightly elevated protein concentration ( 20–80 mg/dL), a normal 
glucose concentration, and a normal or mildly elevated opening pressure (100–
350 mmH2O). Organisms are not seen on Gram’s stain of CSF. The total CSF 
cell count in viral meningitis is typically 25–500/μL, although cell counts of 
several thousand/μL are occasionally seen, especially with infections due to 
lymphocytic choriomeningitis virus (LCMV) and mumps virus
[21]
. 
Lymphocytes are typically the predominant cell. Rarely, PMNs may 
predominate in the first 48 h of illness, especially with infections due to 
echovirus 9, West Nile virus, eastern equine encephalitis (EEE) virus, or 
mumps. A PMN pleocytosis occurs in 45% of patients with West Nile virus 
(WNV) meningitis and can persist for a week or longer before shifting to a 
lymphocytic pleocytosis. PMN pleocytosis with low glucose may also be a 
feature of cytomegalovirus (CMV) infections in immunocompromised hosts. 
Despite these exceptions, the presence of a CSF PMN pleocytosis in a patient 
with suspected viral meningitis in whom a specific diagnosis has not been 
established should prompt consideration of alternative diagnoses, including 
bacterial meningitis or parameningeal infections. The CSF glucose 
concentration is typically normal in viral infections, although it may be 
decreased in 10–30% of cases due to mumps or LCMV. Rare instances of 
decreased CSF glucose concentration occur in cases of meningitis due to 
echoviruses and other enteroviruses, HSV-2, and VZV. As a rule, a 
lymphocytic pleocytosis with a low glucose concentration should suggest 
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fungal or tuberculous meningitis, Listeria meningoencephalitis, or 
noninfectious disorders (e.g., sarcoid, neoplastic meningitis). 
A number of tests measuring levels of various CSF proteins,enzymes, 
and mediators—including C-reactive protein, lactic acid, lactate 
dehydrogenase, neopterin, quinolinate, IL-1β, IL-6, soluble IL-2 receptor, β2-
microglobulin, and TNF—have been proposed as potential discriminators 
between viral and bacterial meningitis or as markers of specific types of viral 
infection (e.g., infection with HIV),but they remain of uncertain sensitivity and 
specificity and are not widely used for diagnostic purposes. 
Amplification of viral-specific DNA or RNA from CSF using PCR 
amplification has become the single most important method for diagnosing 
CNS viral infections. In both enteroviral and HSV infections of the CNS, CSF 
PCR has become the diagnostic procedure of choice and is substantially more 
sensitive than viral cultures. HSV CSF PCR is also an important diagnostic test 
in patients with recurrent episodes of “aseptic” meningitis, many of whom have 
amplifiable HSV DNA in CSF despite negative viral cultures. CSF PCR is also 
used routinely to diagnose CNS viral infections caused by CMV, Epstein-Barr 
virus (EBV), VZV, and human herpesvirus 6 (HHV-6).
[21][22]
 CSF PCR tests 
are available for WNV but are not as sensitive as detection of WNV specific 
CSF IgM. PCR is also useful in the diagnosis of CNS infection caused by 
Mycoplasma pneumoniae, which can mimic viral meningitis and encephalitis. 
PCR of throat washings may assist in diagnosis of enteroviral and mycoplasmal 
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CNS infections. PCR of stool specimens may also assist in diagnosis of 
enteroviral infections .
[21][22] 
The sensitivity of CSF cultures for the diagnosis of viral meningitis and 
encephalitis, in contrast to its utility in bacterial infections, is generally poor. In 
addition to CSF, specific viruses may also be isolated from throat swabs, stool, 
blood, and urine. Enteroviruses and adenoviruses may be found in feces; 
arboviruses, some enteroviruses, and LCMV in blood; mumps and CMV in 
urine; and enteroviruses, mumps, and adenoviruses in throat washings. During 
enteroviral infections, viral shedding in stool may persist for several weeks. 
The presence of enterovirus in stool is not diagnostic and may result from 
residual shedding from a previous enteroviral infection; it also occurs in some 
asymptomatic individuals during enteroviral epidemics.
[21]
 
For many arboviruses including WNV, serologic studies remain 
important diagnostic tools. Serum antibody determination is less useful for 
viruses with high seroprevalence rates in the general population such as HSV, 
VZV, CMV, and EBV. For viruses with low seroprevalence rates, diagnosis of 
acute viral infection can be made by documenting seroconversion between 
acute-phase and convalescent sera (typically obtained after 2–4 weeks) or by 
demonstrating the presence of virus-specific IgM antibodies. For viruses with 
high seroprevalence such as VZV and HSV, demonstration of synthesis of 
virus-specific antibodies in CSF, as shown by an increased IgG index or the 
presence of CSF IgM antibodies, may be useful and can provide presumptive 
evidence of CNS infection. Although serum and CSF IgM antibodies generally 
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persist for only a few months after acute infection, there are exceptions to this 
rule. For example, WNV serum IgM has been shown to persist in some patients 
for >1 year following acute infection. Unfortunately, the delay between onset 
of infection and the host’s generation of a virus-specific antibody response 
often means that serologic data are useful mainly for the retrospective 
establishment of a specific diagnosis, rather than in aiding acute diagnosis or 
management. In the case of EBV, demonstration of antibody responses 
consistent with recent/acute infection (e.g., IgM viral capsid antibody, antibody 
against early antigen, absence of antibody against EBV associated nuclear 
antigen) may assist in diagnosis. CSF oligoclonal gamma globulin bands occur 
in association with a number of viral infections.
[22]
 The associated antibodies 
are often directed against viral proteins. Oligoclonal bands also occur 
commonly in certain noninfectious neurologic diseases (e.g., multiple sclerosis) 
and may befound in nonviral infections (e.g., neurosyphilis, Lyme 
neuroborreliosis). 
CSF in cryptococcal meningitis shows a lymphocytic pleocytosis with 
exceptionally high protein levels. CSF may, however, be normal in exclusively 
parenchymal disease. CSF India ink preparation shows the polysaccharide 
capsule of the cryptococcus as a clear ‘halo’ surrounding the organism. CSF 
staining and culture may yield positive results if adequate samples are obtained. 
Cryptococcal latex antigen detection test relies on agglutination tested at 
differing titres of CSF and has a sensitivity of 90%. Imaging may reveal 
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meningeal enhancement, abscesses, cryptococcomas, gelatinous ,pseudocysts 
and hydrocephalus 
CSF CHLORIDE : 
CSF chloride levels were done in the past about 60 years back and were 
consistently reduced in cases of TB meningitis.In their basic text on the 
cerebrospinal fluid,merritt and fremont-smith frequently referred to the work of 
mestrezat, pointing out that he was the first to emphasize the diagnostic value 
of the spinal fluid chloride content. but whereas mestrezat implied that the 
reduction in chloride content of the cerebrospinal fluid in pyogenic and 
tuberculous meningitis was part of the disease process, merritt regarded the fall 
in chloride as a reflection of the decline in serum chloride. mestrezat said that 
very low values were pathognomonic of tuberculous meningitis,but merritt and 
fremont-smith noted that their results showed this not to be true consistently. 
     CSF chloride levels normal range was 116 – 127 meq/dl. This was found to 
be reduced in TB meningitis ranging from low to low normal. In bacterial 
meningitis it was low normal to the maximum, only a few observations were 
low. CSF chloride levels and it’s relationship with serum chloride remains a 
point of contention. The mechanism of its reduction whether it can be solely 
attributed to the alterations in serum chloride values is unanswered. Chloride is 
measured ion exchange through selective electrodes. 
All patients with suspected viral meningitis should have a complete 
blood count and differential, liver and renal function tests, erythrocyte 
sedimentation rate (ESR), and C-reactive protein, electrolytes, glucose, creatine 
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kinase, aldolase, amylase, and lipase. Neuroimaging studies (MRI preferable to 
CT) are not absolutely necessary in patients with uncomplicated viral 
meningitis but should be performed in patients with altered consciousness, 
seizures, focal neurologic signs or symptoms, atypical CSF profiles, or 
underlying immunocompromising treatments or conditions. 
 
MANAGEMENT 
Management of patient suspected with CNS infection 
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 Bacterial meningitis is a medical emergency. The goal is to begin 
antibiotic therapy within 60 min of a patient’s arrival in the emergency room. 
Empirical antimicrobial therapy is initiated in patients with suspected bacterial 
meningitis before the results of CSF Gram’s stain and culture are known. S. 
pneumoniae and N. meningitidis are the most common etiologic organisms of 
community-acquired bacterial meningitis. 
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Due to the emergence of penicillin- and cephalosporin-resistant S. 
pneumoniae, empirical therapy of community-acquired suspected bacterial 
meningitis in children and adults should include a combination of 
dexamethasone, a third- or fourth-generation cephalosporin(e.g., ceftriaxone, 
cefotaxime, or cefepime), and vancomycin, plus acyclovir, as HSV encephalitis 
is the leading disease in the differential diagnosis, and doxycycline during tick 
season to treat tick-borne bacterial infections. Ceftriaxone or cefotaxime 
provides good coverage for susceptible S. pneumoniae, group B streptococci, 
and H.influenzae and adequate coverage for N. meningitidis.
[3][4][5]
 Cefepime is 
a broad-spectrum fourth-generation cephalosporin with in vitro activity similar 
to that of cefotaxime or ceftriaxone against S. pneumonia and N. meningitidis 
and greater activity against Enterobacter species and Pseudomonas 
aeruginosa. In clinical trials, cefepime has been demonstrated to be equivalent 
to cefotaxime in the treatment of penicillin-sensitive pneumococcal and 
meningococcal meningitis, and it has been used successfully in some patients 
with meningitis due to Enterobacter species and P. aeruginosa. Ampicillin 
should be added to the empirical regimen for coverage of L. monocytogenes in 
individuals <3 months of age, those >55, or those with suspected impaired cell-
mediated immunity because of chronic illness, organ transplantation, 
pregnancy, malignancy, or immunosuppressive therapy. Metronidazole is 
added to the empirical regimen to cover gram-negative anaerobes in patients 
with otitis, sinusitis, or mastoiditis.
[12][13] 
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In hospital-acquired meningitis, and particularly meningitis following 
neurosurgical procedures, staphylococci and gram-negative organisms 
including P. aeruginosa are the most common etiologic organisms. In these 
patients, empirical therapy should include a combination of vancomycin and 
ceftazidime, cefepime, or meropenem. Ceftazidime, cefepime, or meropenem 
should be substituted for ceftriaxone or cefotaxime in neurosurgical patients 
and in neutropenic patients, because ceftriaxone and cefotaxime do not provide 
adequate activity against CNS infection with P. aeruginosa. Meropenem is a 
carbapenem antibiotic that is highly active in vitro against L.monocytogenes, 
has been demonstrated to be effective in cases of meningitis caused by P. 
aeruginosa, and shows good activity against penicillin-resistant pneumococci. 
In experimental pneumococcal meningitis, meropenem was comparable to 
ceftriaxone and inferior to vancomycin in sterilizing CSF cultures. The number 
of patients with bacterial meningitis enrolled in clinical trials of meropenem 
has not been sufficient to definitively assess the efficacy of this antibiotic. 
          In cases of N. meningitides infection, penicillin G remains the antibiotic 
of choice for meningococcal meningitis caused by susceptible strains. Isolates 
of N. meningitides with moderate resistance to penicillin have been identified 
and are increasing in incidence worldwide. CSF isolates of N. meningitides 
should be tested for penicillin  and ampicillin susceptibility, and if resistance is 
found, cefotaxime or ceftriaxone should be substituted for penicillin. A 7-day 
course of intravenous antibiotic therapy is adequate for uncomplicated 
meningococcal meningitis.
[6]
 The index case and all close contacts should 
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receive chemoprophylaxis with a 2-day regimen of rifampin (600 mg every 12 
h for 2 days in adults and 10 mg/kg every 12 h for 2 days in children >1 year). 
Rifampin is not recommended in pregnant women. Alternatively, adults can be 
treated with one dose of azithromycin (500 mg) or one intramuscular dose of 
ceftriaxone (250 mg). Close contacts are defined as those individuals who have 
had contact with oropharyngeal secretions, either through kissing or by sharing 
toys, beverages, or cigarettes
[11]
. 
Antimicrobial therapy of pneumococcal meningitis is initiated with a 
cephalosporin (ceftriaxone, cefotaxime, or cefepime) and vancomycin. All CSF 
isolates of S. pneumoniae should be tested for sensitivity to penicillin and the 
cephalosporins. Once the results of antimicrobial susceptibility tests are known, 
therapy can be modified accordingly . For S. pneumoniae meningitis, an isolate 
of S. pneumoniae is considered to be susceptible to penicillin with a minimal 
inhibitory concentration (MIC) <0.06 μg/mL and to be resistant when the MIC 
is >0.12 μg/mL. Isolates of S. pneumoniae that have cephalosporin MICs ≤0.5 
μg/mL are considered sensitive to the cephalosporins (cefotaxime, ceftriaxone, 
cefepime). Those with MICs of 1 μg/mL are considered to have intermediate 
resistance, and those with MICs ≥2 μg/mL are considered resistant. For 
meningitis due to pneumococci, with cefotaxime or ceftriaxone MICs ≤0.5 
μg/mL, treatment with cefotaxime or ceftriaxone is usually adequate. For MIC 
>1 μg/mL, vancomycin is the antibiotic of choice. Rifampin can be added to 
vancomycin for its synergistic effect but is inadequate as monotherapy because 
resistance develops rapidly when it is used alone. A 2-week course of 
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intravenous antimicrobial therapy is recommended for pneumococcal 
meningitis
[5][7]
. 
Patients with S. pneumoniae meningitis should have a repeat LP 
performed 24–36 h after the initiation of antimicrobial therapy to document 
sterilization of the CSF. Failure to sterilize the CSF after 24–36 h of antibiotic 
therapy should be considered presumptive evidence of antibiotic resistance. 
Patients with penicillin- and cephalosporin- resistant strains of S. pneumoniae 
who do not respond to intravenous vancomycin alone may benefit from the 
addition of intraventricular vancomycin. The intraventricular route of 
administration is preferred over the intrathecal route because adequate 
concentrations of vancomycin in the cerebral ventricles are not always 
achieved with intrathecal administration. 
Meningitis due to L. monocytogenes is treated with ampicillin for at 
least 3 weeks . Gentamicin is added in critically ill patients (2 mg/kg loading 
dose, then 7.5 mg/kg per day given every 8 h and adjusted for serum levels and 
renal function).The combination of trimethoprim (10–20 mg/kg per day) and 
sulfamethoxazole (50–100 mg/kg per day) given every 6 h may provide an 
alternative in penicillin-allergic patients.
[7][9][11] 
Meningitis due to susceptible strains of S. aureus or coagulase-negative 
staphylococci is treated with nafcillin. Vancomycin is the drug of choice for 
methicillin resistant staphylococci and for patients allergic to penicillin. In 
these patients, the CSF should be monitored during therapy. If the CSF is not 
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sterilized after 48 h of intravenous vancomycin therapy, then either 
intraventricular or intrathecal vancomycin, 20 mg once daily, can be added. 
Third-generation cephalosporins—cefotaxime, ceftriaxone, and ceftazidime—
are equally efficacious for the treatment of gram-negative bacillary meningitis, 
with the exception of meningitis due to P. aeruginosa, which should be  treated 
with ceftazidime, cefepime, or meropenem . A 3-week course of intravenous 
antibiotic therapy is recommended for meningitis due to gram-negative bacilli. 
 
ADJUNCTIVE THERAPY 
The release of bacterial cell-wall components by bactericidal antibiotics 
leads to the production of the inflammatory cytokines IL-1βand TNF-α in the 
subarachnoid space. Dexamethasone exerts its beneficial effect by inhibiting 
the synthesis of IL-1β and TNF-α at the level of mRNA, decreasing CSF 
outflow resistance, and stabilizing the blood-brain barrier. The rationale for 
giving dexamethasone 20 min before antibiotic therapy is that dexamethasone 
inhibits the production of TNF-α by macrophages and microglia only if it is 
administered before these cells are activated by endotoxin
[22].
Dexamethasone 
does not alter TNF-α production once it has been induced. The results of 
clinical trials of dexamethasone therapy in meningitis due to H. influenzae, S. 
pneumoniae, and N. meningitides have demonstrated its efficacy in decreasing 
meningeal inflammation and neurologic sequelae such as the incidence of 
sensorineural hearing loss. The benefits were most striking in patients with 
pneumococcal meningitis. Dexamethasone (10 mg intravenously) was 
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administered 15–20 min before the first dose of an antimicrobial agent, and the 
same dose was repeated every 6 h for 4 days. These results were confirmed in a 
second trial of dexamethasone in adults with pneumococcal meningitis. 
Therapy with dexamethasone should ideally be started 20 min before, or not 
later than concurrent with, the first dose of antibiotics. It is unlikely to be of 
significant benefit if started >6 h after antimicrobial therapy has been initiated. 
Dexamethasone may decrease the penetration of vancomycin into CSF, and it 
delays the sterilization of CSF in experimental models of S. pneumoniae 
meningitis
[6][9]
.  
Available antituberculosis drugs are divided on the basis of efficacy and 
toxicity into first-line [isoniazid (H), rifampicin (R),ethambutol (E), 
pyrazinamide (Z) and streptomycin (S)] and second-line (para-aminosalicylic 
acid, ethanolamine, cycloserine, kanamycin, capreomycin and amikacin) 
agents. Newer second-line drugs like fluoroquinolones (ciprofloxacin or 
ofloxacin) and macrolides (azithromycin and clarythromycin) are used in 
multidrug resistant (MDR) cases or when first-line drugs are not tolerated. 
Isoniazid and rifampicin are bactericidal and other first-line drugs are 
bacteriostatic. Isoniazid, pyrazinamide and ethambutol have good CSF 
penetration and others have poor CSF concentration 
[15][17]
. 
World Health Organization (WHO) recommends use of 4 drugs (HRZE) 
for 2 months followed by 2 drugs (HR) for 6 to 7 months for the treatment of 
TBM. The same drug regimen is prescribed for tuberculoma and spinal disease. 
In spite of WHO recommendations, universal consensus regarding duration of 
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treatment has not developed. The current UK guidelines recommend 12 months 
of anti-tuberculosis treatment (ATT) in uncomplicated cases of TBM 
(including tuberculoma without meningitis) extending to 18 months if 
pyrazinamide is omitted.
[19]
 The American Thoracic Society’s recent 
recommendation is a course of 2 months of HRZ, followed by 4 months of HR 
for adults and 10 months HR for children. In a recent study from South India 
by Venugopal and co-workers, it has been seen that directly observed 
treatment, short-course (DOTS) intermittent regimen is an effective treatment 
for neurotuberculosis. A paradoxical worsening of clinical and laboratory 
parameters has been noted by many clinicians immediately after starting ATT, 
including enlargement of tuberculoma. Addition of corticosteroids may lessen 
this paradoxical response. 
 
Multidrug-Resistant Neurotuberculosis 
Drug resistance may be primary or secondary. Exact incidence of MDR 
of neurotuberculosis is not known due to difficulty in isolating mycobacteria 
from the CSF. In other forms of tuberculosis, prevalence of resistance to any 
drug is 13% to 25% and of MDR is about 13%. Most case reports of MDR 
TBM from India are among immunocompromised patients due to HIV 
infection. There is no standard protocol for the treatment. Every attempt should 
be made to isolate the organism and test for sensitivity. At least two agents to 
which the organism is sensitive are to be continued for a full 18 to 20 
months
[19]
. Despite a substantial literature accumulated over the past 40years, 
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the place of corticosteroids in the treatment of TBM remains unclear. It is most 
beneficial when complications appear. These include raised intra-cranial 
pressure, cerebral oedema, stupor, focal neurological signs, spinal block, 
hydrocephalus and basal opto-chiasmatic arachnoiditis 
Treatment of almost all cases of viral meningitis is primarily 
symptomatic and includes use of analgesics, antipyretics, and antiemetics. 
Fluid and electrolyte status should be monitored. Patients with suspected 
bacterial meningitis should receive appropriate empirical therapy pending 
culture results . Hospitalization may not be required in immunocompetent 
patients with presumed viral meningitis and no focal signs or symptoms, no 
significant alteration in consciousness, and a classic CSF profile (lymphocytic 
pleocytosis, normal glucose, negative Gram’s stain) if adequate provision for 
monitoring at home and medical follow-up can be ensured. 
Immunocompromised patients, patients with significant alteration in 
consciousness, seizures, or the presence of focal signs and symptoms 
suggesting the possibility of encephalitis or parenchymal brain involvement; 
and patients who have an atypical CSF profile should be hospitalized. Oral or 
intravenous acyclovir may be of benefit in patients with meningitis caused by 
HSV-1 or -2 and in cases of severe EBV or VZV infection. Data concerning 
treatment of HSV, EBV, and VZV meningitis are extremely limited. Seriously 
ill patients should probably receive intravenous acyclovir (15–30 mg/kg per 
day in three divided doses), which can be followed by an oral drug such as 
acyclovir (800 mg five times daily), famciclovir (500 mg tid), or valacyclovir 
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(1000 mg tid) for a total course of 7–14 days. Patients who are less ill can be 
treated with oral drugs alone. Patients with HIV meningitis should receive 
highly active antiretroviral therapy. There is no specific therapy of proven 
benefit for patients with arboviral encephalitis, including that caused by WNV. 
Patients with viral meningitis who are known to have deficient humoral 
immunity (e.g., X-linked agammaglobulinemia) and who are not already 
receiving either intramuscular gamma globulin or intravenous immunoglobulin 
(IVIg) should be treated with these agents. Intraventricular administration of 
immunoglobulin through an Ommaya reservoir has been tried in some patients 
with chronic enteroviral meningitis who have not responded to intramuscular or 
intravenous immunoglobulin. Vaccination is an effective method of preventing 
the development of meningitis and other neurologic complications associated 
with poliovirus, mumps, measles, rubella, and varicella infection. A live 
attenuated VZV vaccine (Varivax) is available in the United States. Clinical 
studies indicate an effectiveness rate of 70–90% for this vaccine, but a booster 
may be required after ~10 years to maintain immunity. A related vaccine 
(Zostavax) is recommended for prevention of herpes zoster (shingles) in adults 
over the age of 60. An inactivated varicella vaccine is available for transplant 
recipients and others for whom live viral vaccines are contraindicated. 
 
Treatment of cryptococcal meningitis involves  combination chemotherapy 
with conventional amphotericin B and flucytosine for 2 to 4 weeks and then 
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switching to fluconazole for 8 weeks. Lifelong  flucanazole therapy is indicated 
in patients with AIDS. 
Amphotericin B is an effective agent for most CNS mycoses. 
Amphotericin B is a polyene antibiotic that binds to ergosterols in the fungal 
cell wall and disrupts the cell wall integrity leading to increased permeabilty, K 
+ leakage and cell death. Depending on its concentration, it can be fungistatic 
or fungicidal. It is used in a dose of 0.3 to 1.5 mg/kg body weight per day 
intravenously daily as a 1 to 4 hour infusion. It has poor penetration of 
bloodbrain barrier, reducing its ability to achieve effective fungicidal levels in 
the brain. Side effects include renal toxicity, hypokalaemia, hypomagnesaemia, 
normocytic normochromic anaemia and ‘flu-like’ allergic reaction during or 
after intravenous infusion. Lipid-based amphotericin B compounds although 
costlier have lesser adverse effects. Most CNS fungal infections require long 
treatment periods of 4 to 10 weeks often guided by CSF culture reports. 
Oral flucytosine, a cytosine analogue, commonly used as an adjunct to 
amphotericin B in case of invasive infections with Cryptococcus, Candida and 
Aspergillus, is usually well tolerated but may rarely cause bone marrow 
suppression, especially with concomitant use of amphotericin B. 
Azoles (ketoconazole, fluconazole, itraconazole, voriconazole) although 
broad-spectrum are weak antifungals. They have good bioavailability on oral 
administration and are usually well tolerated. 
 
 
  
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 
STUDY CENTRE: 
Madras Medical College and Rajiv Gandhi Government General 
Hospital, Chennai – 600003. 
 
STUDY DESIGN:  
Single centre observational study 
 
SAMPLE SIZE: 
100 meningitis patients admitted in medical wards  based on 
inclusion and exclusion criteria. 
 
STUDY DURATION: 
          July 2017 – June 2018 
ETHICAL ISSUES: 
Approval from Institutional Ethics Committee was taken before starting 
the study. Prior informed consent was obtained from all the patients and 
controls. 
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INCLUSION CRITERIA: 
1.Fever,headache with neckstiffness,altered mental status  
2. Age > 14 years 
 
EXCLUSION CRITERIA: 
1. Patients with vomiting,diarrhoea,dka 
2. Patients on drugs like diuretics,corticosteroids and laxatives 
 
STUDY PLAN: 
Sample size was calculated using the formula 4*pq/d, where p denotes 
the prevalence of the disease, q = 1-p and d denotes the error range. About 100 
patients admitted to the medical wards with the diagnosis of meningitis were 
chosen. A complete history was taken from the patients and the attenders 
including history of chronic kidney disease, previous history of treatment for 
diabetes, hypertension , history of immunocompromised states .Through 
physical examination done looking specifically for clinical signs of meningitis 
and documented. Basic blood investigations were done including a complete 
blood count, liver function test, PT/INR, renal function test, CSF studies like 
sugar, protein, LDH, culture and sensitivity, Gram staining, AFB staining, 
fungal culture, india ink, Gene expert for MTB, CSF chloride level and Serum 
chloride levels done. Imaging studies like CT Brain AND MRI Brain with 
contrast and MRS done. 
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STATISTICAL ANALYSIS: 
Data analysed using statistical package - SPSS Software 
 
CONSENT: 
Written informed consent was obtained from the participating 
patients/attenders. 
 
 
 
 
 
 
 
 
 
 
 
 
                 
 
 
 
 
 
 
 
      
  
 
 
OBSERVATION AND RESULTS 
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OBSERVATION AND RESULTS 
 
Frequency Table 
 
Age group Frequency Percent 
up to 20 
years 
13 13.0 
21-30 years 22 22.0 
31-40 years 24 24.0 
41-50 years 21 21.0 
51-60 years 16 16.0 
60-70 years 4 4.0 
Total 100 100.0 
 
SEX Frequency Percent 
Male 51 51.0 
Female 49 49.0 
Total 100 100.0 
 
PAST 
HISTORY 
Frequency Percent 
DM 25 25.0 
DM/HT 3 3.0 
DM/HT/CAD 1 1.0 
HEAD 
INJURY 
1 1.0 
HEAD 
INJURY/ 
DM 
1 1.0 
HIV 5 5.0 
NIL 64 64.0 
Total 100 100.0 
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CSF 
CYTOLOGY 
Frequency Percent 
Acellular 45 45.0 
Predominantly 
Lymphocytes 
37 37.0 
Predominantly 
PMN 
18 18.0 
Total 100 100.0 
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CSF GRAM 
STAIN 
Frequency Percent 
Gram 
Negative 
Coccobacillus 
1 1.0 
Gram 
Negative 
Diplococcus 
1 1.0 
Gram 
Positive 
Coccus 
8 8.0 
Nil 90 90.0 
Total 100 100.0 
 
CSF 
CUL&SENSITIVITY 
Frequency Percent 
No growth 95 95.0 
S.pneumoniae 5 5.0 
Total 100 100.0 
 
CSFGENE   
EXPERT Frequency Percent 
MTB DETECTED 22 22.0 
MTB NOT 
DETECTED 
78 78.0 
Total 100 100.0 
 
 
 
CSF INDIA INK Frequency Percent 
Negative 3 3.0 
Not done 96 96.0 
Positive 1 1.0 
Total 100 100.0 
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SERUM  CHLORIDE 
meq/l Frequency Percent 
90.00 1 1.0 
91.00 2 2.0 
92.00 3 3.0 
93.00 2 2.0 
94.00 5 5.0 
95.00 4 4.0 
96.00 8 8.0 
97.00 5 5.0 
98.00 5 5.0 
99.00 15 15.0 
100.00 9 9.0 
101.00 6 6.0 
102.00 3 3.0 
103.00 8 8.0 
104.00 11 11.0 
105.00 8 8.0 
106.00 4 4.0 
107.00 1 1.0 
Total 100 100.0 
 
MRI BRAIN MRS WITH 
CONTRAST Frequency Percent 
FEATURES S/O  MENINGITIS 10 10.0 
FEATURES S/O BACTERIAL 
MENINGITIS 
23 23.0 
FEATURES S/O CRYPTOCOCCAL 
MENINGOENCEPHALITIS 
1 1.0 
FEATURES S/O HSV 
MENINGOENCEPHALITIS 
4 4.0 
FEATURES S/O TB MENINGITIS 35 35.0 
FEATURES S/O VIRAL 
MENINGITIS 
10 10.0 
NORMAL STUDY 17 17.0 
Total 100 100.0 
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Interpretation: 
The above table depicts the percentage of distribution of  features 
suggestive of meningitis is 10%,of bacterial meningitis is 23%,of cryptococcal 
meningoencephalitis is 1%,of meningoencephalitis is 4%, of TB meningitis is 
35%,of viral meningitis is 10%,of normal study is 17% in MRI of brain  and 
MRS with contrast. 
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DIAGNOSIS Frequency Percent 
BACTERIAL 
MENINGITIS 
36 36.0 
FUNGAL 
MENINGITIS 
1 1.0 
TB MENINGITIS 35 35.0 
VIRAL MENINGITIS 28 28.0 
Total 100 100.0 
 
 
 
 
Interpretation: 
The above table depicts the diagnosis of meningitis percentage bacterial 
meningitis is 36% and fungal meningitis is 1% ,TB meningitis is 35%,and viral 
meningitis is 28%. 
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CSF chloride Frequency Percent 
>121 23 23.0 
117-120 37 37.0 
113-116 24 24.0 
108-112 16 16.0 
Total 100 100.0 
 
 
Interpretation: 
The above table depicts the CSF chloride levels frequency along with 
percentage >121 is 23%,117-120 is 37%.113-116 is 24%,108-112 is 16%.  
23% 
37% 
24% 
16% 
CSF chloride  
>121
117-120
113-116
108-112
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Cross tab 
 
CSF chloride 
Total >121 117-120 113-116 108-112 
Age group up to 
20 
years 
Count 3 6 4 0 13 
% 13.0% 16.2% 16.7% .0% 13.0% 
21-30 
years 
Count 4 9 5 4 22 
% 17.4% 24.3% 20.8% 25.0% 22.0% 
31-40 
years 
Count 5 8 8 3 24 
% 21.7% 21.6% 33.3% 18.8% 24.0% 
41-50 
years 
Count 7 4 6 4 21 
% 30.4% 10.8% 25.0% 25.0% 21.0% 
51-60 
years 
Count 4 7 1 4 16 
% 17.4% 18.9% 4.2% 25.0% 16.0% 
60-70 
years 
Count 0 3 0 1 4 
% .0% 8.1% .0% 6.3% 4.0% 
Total Count 23 37 24 16 100 
% 100.0% 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=14.095 p=0.518 
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Interpretation: 
The above table depicts the age group of the patients according to their 
CSF chloride group from 20 years to 70 years . 
. 
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Cross tab 
 
CSF chloride 
Total >121 117-120 113-116 108-112 
SEX Male Count 10 20 12 9 51 
% 43.5% 54.1% 50.0% 56.3% 51.0% 
Female Count 13 17 12 7 49 
% 56.5% 45.9% 50.0% 43.8% 49.0% 
Total Count 23 37 24 16 100 
% 100.0% 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=0.845 p=0.839 
 
 
 
Interpretation: 
The above table depicts the sex of patients according to their CSF 
chloride levels (>121,117-120,113-116,108-112).  
44% 
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54% 
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50% 50% 
56% 44% 
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100%
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200%
250%
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>121 117-120 113-116 108-112
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Cross tab 
 
CSF chloride 
Total 
>121 
117-
120 
113-
116 
108-
112 
PAST 
HISTORY 
DM 
Count 5 11 2 7 25 
% 21.7% 29.7% 8.3% 43.8% 25.0% 
DM/HT 
Count 0 2 0 1 3 
% .0% 5.4% .0% 6.3% 3.0% 
DM/HT/CAD 
Count 0 1 0 0 1 
% .0% 2.7% .0% .0% 1.0% 
HEAD 
INJURY 
Count 0 1 0 0 1 
% .0% 2.7% .0% .0% 1.0% 
HEAD 
INJURY/ 
DM 
Count 1 0 0 0 1 
% 4.3% .0% .0% .0% 1.0% 
HIV 
Count 0 0 5 0 5 
% .0% .0% 20.8% .0% 5.0% 
NIL 
Count 17 22 17 8 64 
% 73.9% 59.5% 70.8% 50.0% 64.0% 
Total 
Count 23 37 24 16 100 
% 100.0% 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=37.757* p=0.023 
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Interpretation: 
The above table depicts the past history of patients like 
DM,DM/HT,DM/HT/CAD,HEAD INJURY,HEAD INJURY/DM, HIV. NIL  
according to their CSF chloride levels. 
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Cross tab 
 
CSF chloride 
Total 
>121 
117-
120 
113-
116 
108-
112 
CSF 
CYTOLOG
Y 
Acellular 
Coun
t 
14 17 8 6 45 
% 60.9% 45.9% 33.3% 37.5% 45.0% 
Predominantl
y 
Lymphocytes 
Coun
t 
8 10 13 6 37 
% 34.8% 27.0% 54.2% 37.5% 37.0% 
Predominantl
y PMN 
Coun
t 
1 10 3 4 18 
% 4.3% 27.0% 12.5% 25.0% 18.0% 
Total 
Coun
t 
23 37 24 16 100 
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
Pearson Chi-Square=10.054  p=0.122 
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Interpretation: 
The above table depicts the CSF cytology like acellular,predominant 
lymphocytes, predominantly PMN’s percentage according to its CSF chloride 
levels.  
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Cross tab 
 
CSF chloride 
Total 
>121 
117-
120 
113-
116 
108-
112 
CSF 
GRAM 
STAIN 
NIL 
Count 0 1 0 0 1 
% .0% 2.7% .0% .0% 1.0% 
Gram 
Negative 
Coccobacillus 
Count 0 0 0 1 1 
% .0% .0% .0% 6.3% 1.0% 
Gram 
Negative 
Diplococcus 
Count 0 1 0 0 1 
% .0% 2.7% .0% .0% 1.0% 
Gram 
Positive 
Coccus 
Count 1 6 1 0 8 
% 4.3% 16.2% 4.2% .0% 8.0% 
Nil 
Count 22 29 23 15 89 
% 95.7% 78.4% 95.8% 93.8% 89.0% 
Total 
Count 23 37 24 16 100 
% 100.0% 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=14.632  p=0.262 
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Interpretation: 
The above table depicts the CSF gram stain of the patients compared to  
CSF chloride levels. 
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Cross tab 
 
CSF chloride 
Total 
>121 
117-
120 
113-
116 
108-
112 
CSF 
CUL&SENSITIVI
TY 
No Growth 
Cou
nt 
22 35 22 16 95 
% 95.7% 94.6% 91.7% 
100.0
% 
95.0% 
S.pneumoni
ae 
Cou
nt 
1 2 2 0 5 
% 4.3% 5.4% 8.3% .0% 5.0% 
Total 
Cou
nt 
23 37 24 16 100 
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
Pearson Chi-Square=1.437  p=0.697 
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Interpretation: 
The above table depicts the CSF culture & sensitivity of the patients 
with no growth and S.pneumoniae according to their CSF chloride levels. 
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Cross tab 
 
CSF chloride 
Total 
>121 
117-
120 
113-
116 
108-
112 
CSF 
GENE 
EXPERT 
MTB 
DETECTED 
Count 0 6 8 8 22 
% .0% 16.2% 33.3% 50.0% 22.0% 
MTB NOT 
DETECTED 
Count 23 31 16 8 78 
% 100.0% 83.8% 66.7% 50.0% 78.0% 
Total 
Count 23 37 24 16 100 
% 100.0% 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=16.315**p=0.001 
 
 
Interpretation: 
The above table depicts the CSF gene expert of the patients with MTB  
and without MTB compared to their CSF chloride levels. 
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Cross tab 
 
CSF chloride 
Total 
>121 
117-
120 
113-
116 
108-
112 
CSF INDIA 
INK 
Negative 
Count 0 0 3 0 3 
% .0% .0% 12.5% .0% 3.0% 
Not done 
Count 23 37 20 16 96 
% 100.0% 100.0% 83.3% 100.0% 96.0% 
Positive 
Count 0 0 1 0 1 
% .0% .0% 4.2% .0% 1.0% 
Total 
Count 23 37 24 16 100 
% 100.0% 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=13.194*  p=0.040 
 
 
Interpretation: 
The above table depicts patients in whom CSF india ink was negative, 
positive & not done according to their CSF chloride levels.  
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Descriptives 
  
 
N 
Me
an 
Std. 
Devia
tion 
Std
. 
Err
or 
95% 
Confidenc
e Interval 
for Mean Mini
mum 
Maxi
mum 
  
Lo
wer 
Bou
nd 
Up
per 
Bou
nd 
F 
value 
P 
valu
e 
AGE 
>121 23 
37.
61 
12.02 
2.5
1 
32.
41 
42.
81 
18.00 55.00 
1.264 .291 
117-
120 
37 
37.
38 
15.24 
2.5
1 
32.
30 
42.
46 
16.00 69.00 
113-
116 
24 
33.
46 
10.66 
2.1
8 
28.
96 
37.
96 
16.00 52.00 
108-
112 
16 
41.
75 
13.81 
3.4
5 
34.
39 
49.
11 
21.00 65.00 
Total 100 
37.
19 
13.37 
1.3
4 
34.
54 
39.
84 
16.00 69.00 
CSF 
SUGAR
mg/dl 
>121 23 
53.
96 
11.64 
2.4
3 
48.
92 
58.
99 
26.00 73.00 
18.59
4** 
.p<0
001 
117-
120 
37 
39.
03 
11.52 
1.8
9 
35.
18 
42.
87 
23.00 66.00 
113-
116 
24 
32.
13 
5.71 
1.1
6 
29.
72 
34.
53 
25.00 53.00 
108-
112 
16 
34.
56 
13.26 
3.3
1 
27.
50 
41.
63 
22.00 66.00 
Total 100 
40.
09 
13.34 
1.3
3 
37.
44 
42.
74 
22.00 73.00 
CSF 
PROTEI
N 
mg/dl 
>121 23 
46.
39 
62.43 
13.
02 
19.
39 
73.
39 
20.00 
323.0
0 
21.91
2** 
.p<0
001 
117-
120 
37 
157
.46 
84.24 
13.
85 
129
.37 
185
.55 
30.00 
375.0
0 
113-
116 
24 
204
.25 
82.04 
16.
75 
169
.61 
238
.89 
99.00 
455.0
0 
108-
112 
16 219 73.84 18. 180 258 115.0 356.0
76 
 
.38 46 .03 .72 0 0 
Total 100 
153
.05 
99.16 
9.9
2 
133
.37 
172
.73 
20.00 
455.0
0 
CSF 
LDH U/L 
>121 23 
57.
51 
62.15 
12.
96 
30.
64 
84.
39 
21.90 
266.4
0 
6.338
** 
.p<0
001 
117-
120 
37 
183
.69 
145.6
4 
23.
94 
135
.13 
232
.25 
33.50 
631.7
0 
113-
116 
24 
148
.38 
85.86 
17.
53 
112
.12 
184
.63 
52.00 
421.6
0 
108-
112 
16 
160
.79 
106.0
9 
26.
52 
104
.26 
217
.32 
53.00 
454.3
0 
Total 100 
142
.53 
119.8
5 
11.
98 
118
.75 
166
.31 
21.90 
631.7
0 
SERUM
CHLORI
DE meq/l 
>121 23 
103
.70 
2.16 .45 
102
.76 
104
.63 
99.00 
107.0
0 
31.86
3** 
.p<0
001 
117-
120 
37 100
.14 
3.16 .52 99.
08 
101
.19 
92.00 105.0
0 
113-
116 
24 98.
33 
3.16 .64 97.
00 
99.
67 
92.00 105.0
0 
108-
112 
16 94.
56 
3.18 .80 92.
87 
96.
26 
90.00 103.0
0 
Total 100 99.
63 
4.13 .41 98.
81 
100
.45 
90.00 107.0
0 
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Interpretation: 
The above table depicts the age, CSF sugar mg/dl, CSF protein mg/dl, 
CSF LDH U/L, Serum chloride meq/L of the patients and compares it with 
CSF chloride and provides mean,standard deviation along with standard error. 
The table also shows significant p value in CSF Sugar,CSF Protein, CSF LDH 
compared to CSF chloride levels.  
37.61 
53.96 
46.39 
57.51 
103.73 
37.38 39.03 
157.46 
183.69 
100.14 
33.46 32.13 
204.25 
148.38 
98.33 
41.75 
34.56 
219.38 
160.79 
94.56 
0
50
100
150
200
250
AGE CSF SUGAR mgdi CSF PROTEIN mgdi CSF LDH UL SERUM CHLORIDE
megl>121 117-120 113-116 108-112
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Descriptives     
 
N 
Me
an 
Std. 
Devi
ation 
St
d. 
Er
ror 
95% 
Confiden
ce 
Interval 
for Mean 
Mini
mu
m 
Maxi
mum 
    
Lo
wer 
Bo
und 
Up
per 
Bo
und 
    
AGE 
BACT
ERIA
L 
MENI
NGITI
S 
3
6 
38.
22 
13.7
9 
2.
30 
33.
55 
42.
89 
16.0
0 
69.0
0 
.185 .907 
TB 
MENI
NGITI
S 
3
5 
36.
49 
14.4
6 
2.
44 
31.
52 
41.
45 
16.0
0 
65.0
0 
VIRA
L 
MENI
NGITI
S 
2
8 
36.
54 
11.9
0 
2.
25 
31.
92 
41.
15 
18.0
0 
57.0
0 
FUNG
AL  
MENI
NGITI
S 
1 
43.
00 
. . . . 
43.0
0 
43.0
0 
Total 
1
0
0 
37.
19 
13.3
7 
1.
34 
34.
54 
39.
84 
16.0
0 
69.0
0 
CSF SUGAR 
mg/dl 
BACT
ERIA
L 
MENI
NGITI
S 
3
6 
34.
78 
10.1
6 
1.
69 
31.
34 
38.
22 
22.0
0 
66.0
0 
38.1
33*
* 
<.00
1 
TB 
MENI
NGITI
S 
3
5 
33.
23 
8.44 
1.
43 
30.
33 
36.
13 
24.0
0 
56.0
0 
VIRA
L 
MENI
2
8 
55.
75 
8.62 
1.
63 
52.
41 
59.
09 
41.0
0 
73.0
0 
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NGITI
S 
FUNG
AL  
MENI
NGITI
S 
1 
33.
00 
. . . . 
33.0
0 
33.0
0 
Total 
1
0
0 
40.
09 
13.3
4 
1.
33 
37.
44 
42.
74 
22.0
0 
73.0
0 
CSF PROTEIN 
mg/dl 
BACT
ERIA
L 
MENI
NGITI
S 
3
6 
179
.39 
66.4
5 
11
.0
7 
156
.91 
201
.87 
88.0
0 
356.
00 
69.0
58*
* 
.p<0
001 
TB 
MENI
NGITI
S 
3
5 
214
.80 
67.1
2 
11
.3
5 
191
.74 
237
.86 
126.
00 
390.
00 
VIRA
L 
MENI
NGITI
S 
2
8 
31.
21 
4.48 
.8
5 
29.
48 
32.
95 
20.0
0 
38.0
0 
FUNG
AL  
MENI
NGITI
S 
1 
455
.00 
. . . . 
455.
00 
455.
00 
Total 
1
0
0 
153
.05 
99.1
6 
9.
92 
133
.37 
172
.73 
20.0
0 
455.
00 
CSF LDH U/L 
BACT
ERIA
L 
MENI
NGITI
S 
3
6 
245
.45 
135.
34 
22
.5
6 
199
.66 
291
.24 
55.8
0 
631.
70 
30.8
39*
* 
.p<0
001 TB 
MENI
NGITI
S 
3
5 
120
.97 
48.2
7 
8.
16 
104
.39 
137
.55 
53.0
0 
251.
10 
VIRA
L 
MENI
2
8 
40.
39 
11.9
8 
2.
26 
35.
75 
45.
04 
21.9
0 
69.9
0 
80 
 
NGITI
S 
FUNG
AL  
MENI
NGITI
S 
1 
52.
00 
. . . . 
52.0
0 
52.0
0 
Total 
1
0
0 
142
.53 
119.
85 
11
.9
8 
118
.75 
166
.31 
21.9
0 
631.
70 
CSF 
CHLORIDE 
meq/l 
BACT
ERIA
L 
MENI
NGITI
S 
3
6 
117
.19 
3.53 
.5
9 
116
.00 
118
.39 
109.
00 
126.
00 
43.2
06*
* 
.p<0
001 
TB 
MENI
NGITI
S 
3
5 
114
.09 
2.70 
.4
6 
113
.16 
115
.01 
109.
00 
119.
00 
VIRA
L 
MENI
NGITI
S 
2
8 
122
.50 
2.30 
.4
3 
121
.61 
123
.39 
118.
00 
126.
00 
FUNG
AL  
MENI
NGITI
S 
1 
115
.00 
. . . . 
115.
00 
115.
00 
Total 
1
0
0 
117
.57 
4.43 
.4
4 
116
.69 
118
.45 
109.
00 
126.
00 
SERUM 
CHLORIDE 
meq/l 
BACT
ERIA
L 
MENI
NGITI
S 
3
6 
99.
31 
3.27 
.5
4 
98.
20 
100
.41 
90.0
0 
105.
00 
32.6
59*
* 
 .p<
000
1 
TB 
MENI
NGITI
S 
3
5 
96.
57 
3.29 .5
6 
95.
44 
97.
70 
91.0
0 
105.
00 
81 
 
VIRA
L 
MENI
NGITI
S 
2
8 
103
.93 
1.84 .3
5 
103
.21 
104
.64 
99.0
0 
107.
00 
FUNG
AL  
MENI
NGITI
S 
1 98.
00 
. . . . 98.0
0 
98.0
0 
Total 1
0
0 
99.
63 
4.13 .4
1 
98.
81 
100
.45 
90.0
0 
107.
00 
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Interpretation: 
The above table depicts the age, CSF sugar mg/dl, CSF protein mg/dl, CSF 
LDH U/L,CSF chloride meq/L ,Serum chloride meq/L of the patients and each 
compared with diagnosis of bacterial meningitis ,TB meningitis, viral 
meningitis  and fungal meningitis. 
 
 
 
 
 
 
 
 
 
 
 
 
38.22 37.19 
179.39 
245.45 
117.19 
99.31 
36.49 34.78 
214.8 
120.97 1 4.09 
96.57 
36.54 33.23 31.21 40.39 
122.5 
103.93 
43 55.75 
455 
52 
115 
0 
0
50
100
150
200
250
300
350
400
450
500
AGE CSF SUGAR mgdi CSF PROTEIN
mgdi
CSF LDH UL CSF CHLORIDE
megl
SERUM
CHLORIDE meglBACTERIAL MENIGITIS TB MENINGITIS
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Cross tab 
 
MENINGITIS 
Total 
BACTERI
AL 
MENINGI
TIS 
TB 
MENINGI
TIS 
VIRAL 
MENINGI
TIS 
FUNGAL  
MENINGI
TIS 
Age 
grou
p 
up 
to 
20 
yea
rs 
Count 4 5 4 0 13 
% within 
MENINGI
TIS 
11.1% 14.3% 14.3% .0% 
13.0
% 
21-
30 
yea
rs 
Count 9 8 5 0 22 
% within 
MENINGI
TIS 
25.0% 22.9% 17.9% .0% 
22.0
% 
31-
40 
yea
rs 
Count 8 8 8 0 24 
% within 
MENINGI
TIS 
22.2% 22.9% 28.6% .0% 
24.0
% 
41-
50 
yea
rs 
Count 7 7 6 1 21 
% within 
MENINGI
TIS 
19.4% 20.0% 21.4% 100.0% 
21.0
% 
51-
60 
yea
rs 
Count 6 5 5 0 16 
% within 
MENINGI
TIS 
16.7% 14.3% 17.9% .0% 
16.0
% 
60-
70 
yea
rs 
Count 2 2 0 0 4 
% within 
MENINGI
TIS 
5.6% 5.7% .0% .0% 4.0% 
Total 
Count 36 35 28 1 100 
% within 
MENINGI
TIS 
100.0% 100.0% 100.0% 100.0% 
100.0
% 
Pearson Chi-Square=6.419 P=0.972 
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Interpretation: 
The above table depicts the age group of the patients from 20-70 years 
compared to final diagnosis (bacterial meningitis, TB meningitis, viral 
meningitis and fungal meningitis). 
. 
  
11% 
25% 22% 19% 17% 
6% 
14% 
23% 23% 20% 
14% 
6% 
14% 18% 
29% 
21% 18% 
0% 0% 0% 0% 
100% 
0% 0% 
0%
20%
40%
60%
80%
100%
120%
UP TO 20 YEARS 21-30 YEARS 31-40 YEARS 41-50 YEARS 51-60 YEARS 60-70 YEARS
BACTERIAL MENIGITIS TB MENINGITIS
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Cross tab 
 
MENINGITIS 
Total BACTERIAL 
MENINGITIS 
TB 
MENINGITIS 
VIRAL 
MENINGITIS 
FUNGAL  
MENINGITIS 
SEX 
Male 
Count 20 18 13 0 51 
% within 
MENINGITIS 
55.6% 51.4% 46.4% .0% 51.0% 
Female 
Count 16 17 15 1 49 
% within 
MENINGITIS 
44.4% 48.6% 53.6% 100.0% 49.0% 
Total 
Count 36 35 28 1 100 
% within 
MENINGITIS 
100.0% 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=1.577  P=0.666 
 
 
Interpretation: 
The above table depicts the sex of the patients compared with the 
diagnosis of bacterial meningitis ,TB meningitis,viral meningitis or fungal 
meningitis. 
  
56% 
44% 
51% 49% 46% 
54% 
0% 
100% 
0%
20%
40%
60%
80%
100%
120%
MALE FEMALE
BACTERIAL MENIGITIS TB MENINGITIS
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Cross tab 
 
MENINGITIS 
Tota
l 
BACTE
RIAL 
MENIN
GITIS 
TB 
MENIN
GITIS 
VIRAL 
MENIN
GITIS 
FUNGA
L  
MENIN
GITIS 
PAST 
HIST
ORY 
DM 
Count 12 7 6 0 25 
% within 
MENIN
GITIS 
33.3% 20.0% 21.4% .0% 
25.0
% 
DM/HT 
Count 1 2 0 0 3 
% within 
MENIN
GITIS 
2.8% 5.7% .0% .0% 
3.0
% 
DM/HT/
CAD 
Count 1 0 0 0 1 
% within 
MENIN
GITIS 
2.8% .0% .0% .0% 
1.0
% 
HEAD 
INJURY 
Count 1 0 0 0 1 
% within 
MENIN
GITIS 
2.8% .0% .0% .0% 
1.0
% 
HEAD 
INJURY
/ DM 
Count 1 0 0 0 1 
% within 
MENIN
GITIS 
2.8% .0% .0% .0% 
1.0
% 
HIV 
Count 0 4 0 1 5 
% within 
MENIN
GITIS 
.0% 11.4% .0% 100.0% 
5.0
% 
NIL 
Count 20 22 22 0 64 
% within 
MENIN
GITIS 
55.6% 62.9% 78.6% .0% 
64.0
% 
Total 
Count 36 35 28 1 100 
% within 
MENIN
GITIS 
100.0% 100.0% 100.0% 100.0% 
100.
0% 
Pearson Chi-Square = 34.932* P=0.010 
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Interpretation: 
         The above table depicts the  past history of the patients and  noted like 
DM,DM/HT,DM/HT/CAD, HEAD INJURY,HEAD INJURY/DM, HIV. NIL  
compared with the diagnosis of bacterial meningitis ,TB meningitis, viral 
meningitis or fungal meningitis. 
 
 
 
 
 
 
 
 
 
33% 
3% 3% 3% 3% 0% 
56% 
20% 
6% 
0% 0% 0% 
11% 
63% 
21% 
0% 0% 0% 0% 0% 
79% 
0% 0% 0% 0% 0% 
100% 
0% 
0%
20%
40%
60%
80%
100%
120%
DM DM/HT DM/HT/CAD HEAD INJURY HEAD
INJURY/DM
HIV NIL
BACTERIAL MENIGITIS TB MENINGITIS VIRAL MENINGITIS
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Cross tab 
 
MENINGITIS 
Tota
l 
BACTE
RIAL 
MENIN
GITIS 
TB 
MENIN
GITIS 
VIRAL 
MENIN
GITIS 
FUNGA
L  
MENIN
GITIS 
CSF 
CYTOL
OGY 
Acellular 
Count 13 13 19 0 45 
% within 
MENIN
GITIS 
36.1% 37.1% 67.9% .0% 
45.0
% 
Predomi
nantly 
Lympho
cytes 
Count 5 22 9 1 37 
% within 
MENIN
GITIS 
13.9% 62.9% 32.1% 100.0% 
37.0
% 
Predomi
nantly 
PMN 
Count 18 0 0 0 18 
% within 
MENIN
GITIS 
50.0% .0% .0% .0% 
18.0
% 
Total 
Count 36 35 28 1 100 
% within 
MENIN
GITIS 
100.0% 100.0% 100.0% 100.0% 
100.
0% 
Pearson Chi-Square=49.586**  P<0.001 
89 
 
 
 
Interpretation: 
          The above table depicts the CSF cytology compared with diagnosis of 
bacterial meningitis, TB meningitis, viral meningitis or fungal meningitis.  
36% 
14% 
50% 
37% 
63% 
0% 
68% 
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0% 0.0% 
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0% 
0%
20%
40%
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80%
100%
120%
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BACTERIAL MENINGITIS TB MENINGITIS
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Cross tab 
 
MENINGITIS 
Tota
l 
BACTER
IAL 
MENIN
GITIS 
TB 
MENIN
GITIS 
VIRAL 
MENIN
GITIS 
FUNGA
L  
MENIN
GITIS 
CSF 
GR
AM   
STA
IN 
Gram 
Negative 
Coccoba
cillus 
Count 1 0 0 0 1 
% within 
MENIN
GITIS 
2.8% .0% .0% .0% 
1.0
% 
Gram 
Negative 
Diplococ
cus 
Count 1 0 0 0 1 
% within 
MENIN
GITIS 
2.8% .0% .0% .0% 
1.0
% 
Gram 
Positive 
Coccus 
Count 8 0 0 0 8 
% within 
MENIN
GITIS 
22.2% .0% .0% .0% 
8.0
% 
Nil 
Count 26 35 28 1 90 
% within 
MENIN
GITIS 
72.2% 100.0% 100.0% 100.0% 
90.0
% 
Total 
Count 36 35 28 1 100 
% within 
MENIN
GITIS 
100.0% 100.0% 100.0% 100.0% 
100.
0% 
Pearson Chi-Square=19.753*  P=0.019 
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Interpretation: 
The above table depicts the CSF gram stain compared with diagnosis of 
bacterial meningitis ,TB meningitis, viral meningitis and fungal meningitis. 
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Cross tab 
 
MENINGITIS 
Tot
al 
BACT
ERIAL 
MENI
NGITI
S 
TB 
MENI
NGITI
S 
VIRAL 
MENI
NGITI
S 
FUNG
AL  
MENI
NGITI
S 
MRI 
BRAI
N 
MRS 
WITH 
CONT
RAST 
FEATURES 
S/O  
MENINGITIS 
Count 6 0 4 0 10 
% 
within 
MENI
NGITI
S 
16.7% .0% 14.3% .0% 
10.
0% 
FEATURES 
S/O 
BACTERIAL 
MENINGITIS 
Count 23 0 0 0 23 
% 
within 
MENI
NGITI
S 
63.9% .0% .0% .0% 
23.
0% 
FEATURES 
S/O 
CRYPTOCOCC
AL 
MENINGOENC
EOHALITIS 
Count 0 0 0 1 1 
% 
within 
MENI
NGITI
S 
.0% .0% .0% 100.0% 
1.0
% 
FEATURES 
S/O HSV 
MENINGOENC
EPHALITIS 
Count 0 0 4 0 4 
% 
within 
MENI
NGITI
S 
.0% .0% 14.3% .0% 
4.0
% 
FEATURES 
S/O TB 
MENINGITIS 
Count 0 35 0 0 35 
% 
within 
MENI
NGITI
S 
.0% 100.0% .0% .0% 
35.
0% 
FEATURES 
S/O VIRAL 
MENINGITIS 
Count 0 0 10 0 10 
% 
within 
MENI
NGITI
S 
.0% .0% 35.7% .0% 
10.
0% 
NORMAL Count 7 0 10 0 17 
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STUDY % 
within 
MENI
NGITI
S 
19.4% .0% 35.7% .0% 
17.
0% 
Total 
Count 36 35 28 1 100 
% 
within 
MENI
NGITI
S 
100.0% 100.0% 100.0% 100.0% 
100
.0% 
Pearson Chi-Square=255.618** P<0.001 
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Interpretation: 
The above table depicts the MRI of brain  and MRS with contrast ‘s 
features and its percentage of features s/o meningitis is 17%,features s/o 
bacterial meningitis is 64%,features s/o cryptococcal meningoencephalitis is 
1%,features s/o HSV meningoencephalitis is 4%,features s/o TB meningitis is 
35%,features s/o viral meningitis is 10%,normal study is 17%. According to 
their bacterial meningitis, TB meningitis, viral meningitis, fungal meningitis.. 
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DISCUSSION 
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DISCUSSION 
 
The present study was undertaken to compare the cerebrospinal fluid 
chloride levels in  bacterial, tuberculous , viral and fungal meningitis. It also 
compares the cerebrospinal fluid chloride levels along with other investigations 
like CSF sugar, CSF protein, CSF LDH,CSF gram stain, CSF AFB staining, 
CSF culture& sensitivity, CSF fungal culture, CSF gene expert and MRI brain 
with contrast & MRS of 100 meningitis patients in a tertiary care centre. 
 
After getting informed consent from the patients or their relatives 
routine investigations were done which included complete blood hemogram, 
renal function, liver function, serum electrolytes ,CSF studies and imaging 
were done. After ensuring that patient did not have any confounding factors, 
the data was analysed for comparison of the cerebrospinal fluid chloride levels 
in  bacterial, tuberculous , viral and fungal meningitis. 
. 
The present study among a total of hundred patients 51 were males and 
49 were females. 36 patients carried  risk factors/predisposing factors for CNS 
infection.45 % of meningitis patients whose CSF cytology were found to be 
acellular had clinical, laboratory ,microbiological and/or imaging confirmation 
of the presence of meningitis. Gram stain helped in the isolation of 10 cases of 
bacterial meningitis i.e., 27.78 % patients had microbiological confirmation of 
bacterial meningitis. A total of 5 cases were culture positive all the 5 cases had 
S.pneumoniae isolated  suggesting only 13.89% of bacterial meningitis were 
identified by cultures among the 36 cases. 
 
      Among the 100 meningitis patients studied age and sex had  no 
significant co relation with the CSF chloride levels. This is in similar lines to 
studies conducted by Dr. Arthi Ramkissoon in 1985. Gram stain positive or 
Culture & sensitive positive patients were not found to significantly related to 
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CSF chloride levels. Cryptococcal meningoencephalitis were significantly 
related to fall in CSF chloride levels but the total number of cases is just 1 so 
this needs further study as the statistical significance could be baised. The gene 
expert positive patients had a significant lower chloride levels with a p value of 
less than 0.001. CSF chloride levels were found to low/low normal  in more 
than half of the subjects studied proving to be statistically significant when 
compared with CSF protein values, a depiction in lines with Califmed study by 
Dr H. W. Gierson, M.D., and Dr.G. J. Owens. . CSF LDH co relates with the 
CSF chloride levels with a significant p value of< 0.001 found in patients with 
bacterial and TB meningitis 
 
       The study depicted the time tested facts of raised  CSF protein and low 
CSF sugar in bacterial and tuberculous meningitis. Viral meningitis the CSF 
protein ,CSF sugar tend to be within normal range.  Serum chloride levels trend 
were similar to CSF chloride levels with low to low normal levels documented 
. CSF chloride level in bacterial meningitis patients tend to show a statistical 
significant p value found to be <0.001 by having mean CSF chloride level to be 
117.19 meq/dl.  CSF chloride levels in tuberculous meningitis were found to be 
statistically significant with a mean CSF chloride 114. The serum chloride 
levels in comparison to all the types of meningitis were reduced more in 
tuberculous meningitis followed by bacterial meningitis. Similar findings were 
observed in a study conducted in 2003 in Chinese PLA hospital by Dr. 
Q.C.Tan. The comparison ends there as this study excluded bacterial 
meningitis altogether so the trends and whether it could be used as a diagnostic 
test of value cannot be categorically stated. The Chinese PLA hospital  study 
also observed a rapid fall in serum chloride levels in cryptococcal meningitis. 
Cases of viral meningitis had normal CSF chloride levels in the present study. 
The same was observed in the Chinese PLA hospital study  Different  age 
group compared with types of meningitis showed no statistical significance 
with the CSF chloride levels. There was no co relation between sex and 
different types of meningitis with both the sexes almost clocking similar 
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disease pattern with no statistical significance. CSF AFB staining was all in all 
zero also the gram stain and culture yielded  much less than reported 
worldwide reasons for which could be this being tertiary care referral centre 
patients might already be exposed to antibiotics ,given antibiotics prior to 
lumbar puncture, errors in sampling and laboratory errors.  
 
      Among  35 cases of TB meningitis 62.9% were found to be CSF gene 
expert positive against the remaining 31.1% confirmed by other means .MRI 
brain with contrast and MRS was done which detected features of tuberculous 
meningitis in all the cases,it detected 29 cases of bacterial meningitis i.e., 
81.6%   and 18 cases  of all viral meningitis patients accounting to i.e., 81.6%. 
 
       The present study provides confirmation of the studies in the past like Dr. 
Arthi Ramkissoon study, califmed study and Chinese PLA hospital study that 
CSF chloride levels are decreased more in tuberculous meningitis than in 
bacterial meningitis but whether this could be of diagnostic significance cannot 
be concretely stated. It could be at large be taken as indicative. Further 
corrabation and studies could be valuable in throwing light. In this era of 
evidence based medicine this could add to a valuable piece of evidence if not 
the sole evidence. 
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CONCLUSION 
 
In this study the CSF chloride levels are reduced in TB meningitis 
greater than bacterial meningitis. 
 
         In viral meningitis CSF chloride levels were found to be normal. 
 
         CSF chloride levels can be measured in cases of meningitis which could 
give an indication of the etiology considering the cost- effectiveness of the 
investigation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
LIMITATIONS 
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LIMITATIONS 
 
        The study was conducted in a single center -tertiary care referral hospital. 
 
       The CSF profile could have been altered by prior antibiotic usage before 
referral from secondary and primary health care providers. 
 
      The possibility of study containing sick patients since study being 
conducted in a tertiary referral centre. 
 
The study is a cross sectional observational study and follow up details 
were not evaluated. Hence the change in the CSF chloride values after 
treatment could not be documented. 
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A STUDY OF CEREBROSPINAL FLUID CHLORIDE LEVELS IN     
MENINGITIS - PROFORMA 
 
Name : 
Age/Sex : 
OP/IP No : 
Occupation : 
Address : 
Contact No. : 
 
SYMPTOMS 
 Fever 
 Altered sensorium 
 Neck stiffness 
 Altered behaviour 
 
PATIENT CHARACTERISTICS 
 Age 
 Alcoholic 
 Diabetic 
 Immunocompromised state 
 Previous history of neurosurgery / head injury 
 Socioeconomic status 
 Tuberculosis 
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CT BRAIN/ MRI BRAIN WITH CONTRAST AND MRS 
CEREBROSPINAL FLUID ANALYSIS INCLUDING CHLORIDE 
SERUM CHLORIDE 
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INFORMATION SHEET 
We are conducting a study on “A STUDY OF CEREBROSPINAL FLUID 
CHLORIDE LEVELS IN MENINGITIS” among patients attending 
Rajiv  Gandhi Government General Hospital, Chennai and for that your 
specimen may be valuable to us. 
The purpose of this study is to identify the chloride levels in meningitis . 
We are selecting certain cases and if you are found eligible, we may perform 
extra tests and special studies which in any way do not affect your final 
report or management. 
The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in 
the management or treatment. 
 
Signature of Investigator    Signature of Participant 
Date : 
Place : 
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PATIENT CONSENT FORM 
Study Detail : A STUDY OF CEREBROSPINAL FLUID 
CHLORIDE LEVEL IN MENINGITIS 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction.  
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected.  
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree 
to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any  
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data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team 
and to immediately inform the study staff if I suffer from any 
deterioration in my health or well being or any unexpected or unusual 
symptoms.  
I hereby consent to participate in this study.  
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological 
tests.  
 
 
Signature/thumb impression 
Patient’s Name and Address 
 
 
Signature of Investigator 
 
 
Dr.C.GOBINATH
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1 26 F NIL 30 103 ACELLULAR  NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 366.7 118 103 NORMAL STUDY BACTERIAL MENINGITIS
2 52 M DM 44 115 predominantly PMN GRAM NEGATIVE COCCOBACILLUS NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 277 111 95
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
3 17 M NIL 35 169 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB  DETECTED NOT DONE 146 115 97
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
4 33 M NIL 44 35 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 33.5 120 101
FEATURES S/O HSV 
MENINGOENCEPHALITIS VIRAL MENINGITIS
5 39 F NIL 40 108 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 421.6 116 100 NORMAL STUDY BACTERIAL MENINGITIS
6 49 MHEAD INJURY/ DM 28 105 predominantly PMN GRAM POSITIVE COCCUS S.pneumoniae NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 266.4 122 99
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
7 55 M NIL 33 135 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 201.9 112 91 FEATURES S/O TB MENINGITIS TB MENINGITIS
8 43 M DM 58 30 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 25.9 121 105 NORMAL STUDY VIRAL MENINGITIS
9 21 F NIL 24 150 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 139.7 109 94
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
10 33 F NIL 38 219 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 105.6 113 99
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
11 42 M HIV 32 142 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NEGATIVE 82.5 116 104
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
12 20 M NIL 55 32 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 43.3 119 100
FEATURES S/O VIRAL 
MENINGITIS VIRAL MENINGITIS
13 29 F NIL 23 132 predominantly PMN GRAM POSITIVE COCCUS NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 199.7 120 99 FEATURES S/O  MENINGITIS BACTERIAL MENINGITIS
14 38 F DM 32 99 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 230.6 115 100
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
15 53 F DM 29 256 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 125.6 117 96
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
16 34 F NIL 41 37 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 55.9 119 105
FEATURES S/O VIRAL 
MENINGITIS VIRAL MENINGITIS
17 22 M NIL 33 126 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 88.2 109 93
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
18 33 M DM 24 199 predominantly PMN NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 152.7 112 97
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
19 19 F NIL 29 143 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 143.1 120 101 NORMAL STUDY BACTERIAL MENINGITIS
20 22 M NIL 31 211 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 67.8 114 98
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
21 38 M NIL 47 38 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 33.7 123 104
FEATURES S/O VIRAL 
MENINGITIS VIRAL MENINGITIS
22 55 F NIL 55 35 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 28.6 126 102 NORMAL STUDY VIRAL MENINGITIS
23 38 F DM 36 156 predominantly PMN GRAM POSITIVE COCCUS NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 66.4 118 99 NORMAL STUDY BACTERIAL MENINGITIS
24 46 M HIV 27 244 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NEGATIVE 176 114 96
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
25 18 F NIL 44 28 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 66.2 122 104
FEATURES S/O VIRAL 
MENINGITIS VIRAL MENINGITIS
26 23 F NIL 28 177 predominantly PMN NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 556.7 119 101
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
27 39 M NIL 36 193 predominantly PMN NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 327.8 120 103 FEATURES S/O  MENINGITIS BACTERIAL MENINGITIS
28 34 M DM 29 301 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 85.2 110 96
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
29 44 F NIL 50 34 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 43.7 121 99 NORMAL STUDY VIRAL MENINGITIS
30 52 M NIL 66 30 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 52.5 125 104
FEATURES S/O VIRAL 
MENINGITIS VIRAL MENINGITIS
31 28 M NIL 48 34 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 39.7 120 105 NORMAL STUDY VIRAL MENINGITIS
32 16 F NIL 30 255 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 188.4 115 98
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
33 27 M NIL 26 161 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 278.9 113 95
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
34 41 F DM 50 287 predominantly PMN NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 349.5 119 100
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
35 59 F DM/HT 53 188 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 97 112 94 FEATURES S/O TB MENINGITIS TB MENINGITIS
36 62 M DM/HT/CAD 45 105 predominantly PMN GRAM POSITIVE COCCUS S.pneumoniae NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 631.7 119 104
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
37 46 F NIL 32 144 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 98.6 115 97
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
38 36 F NIL 28 233 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 53 111 91
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
39 41 M DM 55 32 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 33.5 126 104
FEATURES S/O VIRAL 
MENINGITIS VIRAL MENINGITIS
40 28 M NIL 33 121 predominantly PMN NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 55.8 116 99 NORMAL STUDY BACTERIAL MENINGITIS
41 21 F NIL 26 190 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 248.1 117 100
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
42 36 F NIL 58 28 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 31.3 125 105 NORMAL STUDY VIRAL MENINGITIS
43 45 M DM 30 88 predominantly PMN GRAM POSITIVE COCCUS S.pneumoniae NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 249 117 92 FEATURES S/O MENINGITIS BACTERIAL MENINGITIS
44 32 F NIL 28 136 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 197 114 96 FEATURES S/O TB MENINGITIS TB MENINGITIS
45 19 F NIL 30 188 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 153.8 117 99
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
46 57 M DM 55 35 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 55.2 120 105 FEATURES S/O  MENINGITIS VIRAL MENINGITIS
47 27 M NIL 66 32 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 47 118 104
FEATURES S/O VIRAL 
MENINGITIS VIRAL MENINGITIS
48 33 F DM 26 168 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 99.9 119 98 FEATURES S/O TB MENINGITIS TB MENINGITIS
49 42 M NIL 32 257 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 176.6 115 105
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
50 26 M NIL 26 323 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 233.7 126 100
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
51 18 F NIL 45 30 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 41.6 123 103 NORMAL STUDY VIRAL MENINGITIS
52 55 F DM 36 129 Predominantly LYMPHOCYTES
GRAM POSITIVE 
COCCUS NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 187.4 119 99 NORMAL STUDY BACTERIAL MENINGITIS
53 35 M NIL 30 199 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 154.4 115 96
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
54 16 M NIL 36 288 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 87.1 117 97
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
55 22 F NIL 53 33 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 32 123 104 NORMAL STUDY VIRAL MENINGITIS
56 29 F NIL 25 390 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 59.9 113 92
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
57 46 M DM 30 183 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 57.7 119 103
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
58 53 M NIL 66 28 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 69.9 122 105 FEATURES S/O  MENINGITIS VIRAL MENINGITIS
59 58 F DM 22 166 predominantly PMN NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 454.3 109 90
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
60 48 F HIV 29 228 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NEGATIVE 169.8 115 105
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
61 36 M NIL 50 30 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 28.9 122 103 NORMAL STUDY VIRAL MENINGITIS
62 41 M NIL 27 156 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 98.7 117 99 FEATURES S/O TB MENINGITIS TB MENINGITIS
63 38 F NIL 31 201 predominantly PMN NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 154.7 119 100
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
64 17 M NIL 34 123 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 188.9 117 102
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
65 29 F NIL 57 28 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 49.6 125 106
FEATURES S/O HSV 
MENINGOENCEPHALITIS VIRAL MENINGITIS
66 43 F HIV 33 455 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED POSITIVE 52 115 98
FEATURES S/O 
CRYPTOCOCCAL 
MENINGOENCEOHALITIS
FUNGAL MENINGITIS
67 58 M DM 51 375 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 91 118 98
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
68 37 F NIL 35 253 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 79.3 115 96
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
69 20 M NIL 29 178 predominantly PMN GRAM POSITIVE COCCUS S.pneumoniae NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 146.5 116 96
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
70 29 F NIL 33 199 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 99.4 120 99 FEATURES S/O  MENINGITIS BACTERIAL MENINGITIS
71 33 F NIL 63 37 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 44.7 125 104 NORMAL STUDY VIRAL MENINGITIS
72 27 M NIL 37 156 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 75 118 100
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
73 45 F DM 73 30 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 33.2 124 102 FEATURES S/O  MENINGITIS VIRAL MENINGITIS
74 35 M HIV 32 177 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 251.1 116 99
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
75 42 M NIL 26 356 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 88.4 111 95
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
76 57 F NIL 30 146 ACELLULAR GRAM POSITIVE COCCUS NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 192.6 119 101
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
77 28 F NIL 25 221 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 136.3 112 93
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
78 20 M NIL 56 32 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 40 125 104 NORMAL STUDY VIRAL MENINGITIS
79 48 F DM 70 35 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 25.8 124 103
FEATURES S/O HSV 
MENINGOENCEPHALITIS VIRAL MENINGITIS
80 53 M DM 45 244 predominantly PMN NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 337.4 117 100 FEATURES S/O  MENINGITIS BACTERIAL MENINGITIS
81 65 F NIL 30 193 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 77.2 111 94
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
82 46 F DM 24 274 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 201.2 112 99
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
83 24 M HEAD INJURY 32 188 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 332.8 118 97
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
84 39 M NIL 55 36 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 21.9 123 107
FEATURES S/O VIRAL 
MENINGITIS VIRAL MENINGITIS
85 26 M NIL 36 277 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 145.7 110 94 FEATURES S/O TB MENINGITIS TB MENINGITIS
86 24 F NIL 47 20 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 31 122 106
FEATURES S/O VIRAL 
MENINGITIS VIRAL MENINGITIS
87 16 F NIL 29 164 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 102.2 115 95
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
88 44 M DM 66 243 predominantly PMN NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 297.4 110 103 NORMAL STUDY BACTERIAL MENINGITIS
89 69 M DM/HT 55 133 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 173.2 119 96
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
90 55 F NIL 52 22 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 41.5 122 106
FEATURES S/O VIRAL 
MENINGITIS VIRAL MENINGITIS
91 16 M NIL 60 215 predominantly PMN GRAM NEGATIVE DIPLOCOCCUS NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 98.6 120 101 FEATURES S/O MENINGITIS BACTERIAL MENINGITIS
92 47 M DM 56 333 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 77.4 111 94
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
93 38 F NIL 33 189 predominantly PMN NIL S.pneumoniae NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 111.4 115 99
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
94 22 M NIL 27 228 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 76.3 113 99 FEATURES S/O TB MENINGITIS TB MENINGITIS
95 41 F DM 67 23 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 47.2 125 106 FEATURES S/O MENINGITIS VIRAL MENINGITIS
96 34 F NIL 65 30 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 33.7 120 104
FEATURES S/O HSV 
MENINGOENCEPHALITIS VIRAL MENINGITIS
97 63 M DM/HT 43 166 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH MTB DETECTED NOT DONE 112.4 117 92
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
98 56 M DM 38 304 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 326.5 118 99
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
99 37 F NIL 34 199 ACELLULAR NIL NO GROWTH NO AFB NO GROWTH MTB NOT DETECTED NOT DONE 356.9 120 103
FEATURES S/O BACTERIAL 
MENINGITIS BACTERIAL MENINGITIS
100 52 M DM 53 175 Predominantly LYMPHOCYTES NIL NO GROWTH NO AFB NO GROWTH
MTB NOT 
DETECTED NOT DONE 132.7 116 101
FEATURES S/O TB 
MENINGITIS TB MENINGITIS
